ISSN 0959-8049
Publisher: Elsevier
< previous issue | all issues | next issue >
Changing concepts in breast cancer management pp. 3-3(1) Author: Veronesi U.
Mammographic-pathologic correlations pp. 4-4(1) Author: Holland R.
Breast conservation therapy - techniques & controversies pp. 4-4(1) Author: O'Higgins N.
Fine needle aspiration cytology (FNAC) vs core biopsy pp. 4-4(1) Author: Svane G.
Quality assurance in surgical management pp. 4-4(1) Author: Mansel R.E.
Digital mammography and multimedial consultation in breast diagnosis pp. 5-5(1) Authors: Del Turco M.R.; Lazzari B.; Ambrogetti D.
Computer aided diagnosis (CAD) in mammography pp. 5-5(1) Authors: Hendriks J.H.; Karsemeyer N.
Nuclear magnetic resonance and breast cancer diagnosis pp. 5-5(1) Author: Kaiser W.A.
The evolution of ultrasonography pp. 5-5(1) Author: Rizzatto G.
Late sequelae of breast cancer treatment: systematic therapy pp. 5-6(2) Author: Rose C.
Cosmetic and functional sequelae related to breast cancer surgery pp. 6-6(1) Author: Christiaens M.R.
Late sequelae of radiotherapy in breast cancer pp. 6-6(1) Author: Jassem J.
Late psychological sequelae of breast cancer pp. 6-6(1) Author: Maguire P.
Training in communication pp. 6-6(1) Author: Razavi D.
Structuring communication in breast cancer care pp. 6-6(1) Author: Postma-Schuit F.C.E.
Preliminary psychometric testing of a comprehensive assessment of satisfaction with care in an oncology institute pp. 6-7(2) Authors: Bredart A.; Razavi D.; Didier F.; Scaffidi E.; Robertson C.; Costa A.
Culture and communication: Approach to patients in clinical research pp. 7-7(1) Authors: Zwitter M.; Cufer T.; Smrdel U.; Therasse P.
How can women affect health policy pp. 7-7(1) Author: Tonge J.
The management of ductal carcinoma in situ pp. 8-8(1) Author: Silverstein M.J.
The role of radiotherapy in breast conserving treatment of ductal carcinoma in situ (DCIS): First results of EORTC trial 10853 pp. 8-8(1)
Classification of ductal carcinoma in situ of the breast in the EORTC 10853 trial: Do subtypes predict risk of recurrence? Results of the central pathology review of the EORTC 10853 DCIS trial pp. 8-8(1) Authors: Bijker N.; Bijker J.L.; Peterse N.; van de Vijver M.; Julien J.P.
Ductal carcinoma in situ: Factors affecting recurrence pp. 8-8(1) Authors: Hiew L.Y.; Stallard S.; Purushotham A.D.; Mehana H.; Cordiner C.; Dobson H.; Mallon E.A.; George W.D.
Ductal carcinoma in situ (DCIS): A comparison of three local treatments in current practice pp. 9-9(1) Authors: Cutuli B.; Velten M.; Duperoux G.; De Lafontan B.; Mignotte H.; Giard S.; Servant V.; Treilleux I.; Lesur A.; Rios M.; Auvray H.; Penaud-Llorca F.
DCIS 3-D reconstruction. A new appraisal of retroareolar and nipple involvment pp. 9-9(1) Authors: Duval C.; Raoust I.; Julien J.P.
Expression of tenascin-C in intraductal carcinoma of human breast: Relation to invasion pp. 9-9(1) Authors: Jahkola T.; Toivonen T.; Nordling S.; von Smitten K.; Virtanen I.
Morphological and clinical characteristics of patients with ipsilateral recurrence after DCIS pp. 9-9(1)
Ductal carcinoma in situ of the breast: Is breast conserving treatment feasible? pp. 9-10(2) Authors: Yamakawa T.; Shinoto M.; Taniki T.; Numoto S.; Ito S.; Morimoto T.
Apoptosis in ductal carcinoma in situ of the breast: its relationship to prognostic markers pp. 10-10(1) Authors: Moreno A.; Figueras A.; Lloveras B.; Griera E.; Escobedo A.
Ductal carcinoma in situ: A revision of 43 cases pp. 10-10(1) Authors: Salicru S.; Sabadell M.D.; Lirola J.L.; Duran A.; Cabaleiro A.; Pedreira A.; Xercavins J.
Local recurrence in women with ductal carcinoma in situ (DCIS) according to the treatment pp. 10-10(1) Authors: Limite G.; Pace U.; Pizzi C.; Riccardi A.; Imbriaco M.; Di Maio M.; Petrella G.; Pettinato G.; Sodano A.; Contegiacomo A.; Forestieri P.
Locally advanced and metastatic breast cancer pp. 10-10(1) Author: Rubens R.D.
99mTc-MIBI scintigraphy evaluates response to neoadjuvant chemotherapy in locally advanced breast cancer pp. 10-11(2) Authors: Festa A.; Tofani A.; Sciuto R.; Semprebene A.; Cucchi R.; Rea S.; Botti C.; Mottolese M.; Benevolo M.; Maini C.L.
Flap recurrence following mastectomy for breast cancer: local failure or systemic disease pp. 11-11(1) Authors: Byrne G.J.; Bronder C.S.; Swindell R.; Howell A.; Bundred N.J.
Determinants of prognosis after first isolated locoregional recurrence of breast cancer pp. 11-11(1)
Identification of recurrent breast cancer with radiolabelled isonitriles pp. 11-11(1) Authors: Buscombe J.R.; Cwikla J.B.; Parbhoo S.P.; Gehani S.; Jones A.L.; Hinton J.; Deery A.; Crow J.; Hilson A.J.W.
Isolated local-regional recurrence of breast cancer: Impact of rediatherapy on dissemination and survival pp. 11-11(1) Authors: Kamby C.; Sengelov L.
Family history of breast cancer and local recurrence after breast conserving therapy pp. 12-12(1)
Epirubicina (EPI) and vinorelbine (VNR): High activity, dose dense regimen for primary breast cancer pp. 12-12(1)
Concurrent paclitaxel and radiation in locally advanced breast cancer pp. 12-12(1) Authors: Formenti C.; Skinner S.; Spicer K.; Cohen D.; Kutsch D.; Symmans K.; Volm F.; Muggia F.M.
Combination of oral idarubicin and cyclophosphamide in the treatment of advanced breast cancer pp. 12-12(1) Authors: Wiltschke C.; Maca M.; Brodowicz T.; Valenta B.; Zielinski C.
Combination chemotherapy with paclitaxel (T) and epirubicin (E) for metastatic breast cancer (MBC): A phase I-II study pp. 12-13(2) Authors: Durando A.; Alabiso O.; Bellino R.; Genta F.; Katsaros D.; Malossi A.; Aidala S.; Mussa A.; Massobrio M.
Timing of combined chemoradiotherapy in the conservative treatment of locally advanced breast cancer (LABC) pp. 13-13(1) Authors: Pierga J.Y.; Campana F.; Laguerre B.; Palangie T.; Fourquet A.; Asselain B.; Dieras V.; Beuzeboc P.; Dorval T.; Scholl S.; Pouillart P.
Primary chemotherapy for locally advanced breast cancer using film as a novel regimen pp. 13-13(1) Authors: Davidson N.; Wood J.; Treves J.; Snooks S.
Letrozole as primary medical therapy for locally advanced and large operable breast cancer pp. 13-13(1) Authors: Dixon J.M.; Love C.D.B.; Tucker S.; Bellamy C.; Leonard R.C.F.; Miller W.R.
Weekly cisplatin-epirubicin-paclitaxel in advanced breast cancer: A phase I study pp. 13-13(1) Authors: Frasci G.; Comella P.; D'Aiuto G.; Apicella A.; Thomas R.; Capasso I.; Frasci G.G.; Comella G.; Cortino G.R.; DiBonito M.; Piccolo S.
Long duration of response with letrozole 2.5 mg (Femara(R)) in two trials in postmenopausal women with advanced breast cancer after anti-estrogen therapy pp. 13-14(2)
Serum hepatocyte growth factor (HGF) levels in patients with progressive metastatic breast cancer pp. 14-14(1) Authors: Maemura M.; Iino Y.; Yokoe T.; Horiguchi J.; Takei H.; Nagaoka H.; Matsumoto H.; Morishita Y.
High-dose chemotherapy with peripheral blood stem cell transplantation as adjuvant therapy for primary breast cancer pp. 14-14(1) Authors: Iwase K.; Maruyama F.; Ohtani S.; Tsujimura T.; Inagaki A.; Hanai T.; Jimbo S.; Kobayashi N.; Yamamoto H.; Asano Y.; Furusawa K.; Tsuzuki M.; Miura K.
Sequential administration of paclitaxel and doxorubicin followed by CMF in women with advanced breast cancer pp. 14-14(1) Authors: Papadimitriou C.; Dimopoulos M.; Lazaris D.; Ampela C.; Louvrou-Fertaki A.; Athanassiades P.; Stamatelopoulos S.; Keramopoulos A.
A randomised clinical trial of primary chemotherapy (PC) with taxol + epirubicin (TE) V.5-FU + epirubicin + cyclophosphamide (FEC) in stage IIIA breast cancer: A preliminary report pp. 14-15(2) Authors: Malamos N.; Papadiamantis I.; Andonopoulos M.; Tsikkinis A.; Kosmas H.; Pallis L.; Kouri E.; Sfikas K.
Sequential doxorubicine (DOX) and docetaxel (DOC) as neoadjuvant chemotherapy in locally advanced breast cancer (LABC): A pilot study pp. 15-15(1) Authors: Wynendaele W.; Paridaens R.; Christiaens M.R.; Van den Bogaert W.; van Oosterom A.T.
Neoadjuvant hormonal therapy in locally advanced breast cancer pp. 15-15(1) Authors: Leal da Silva J.M.; Cardoso F.; Oliveira F.; Cunha H.; Ferreira E.P.
Photodynamic therapy versus laser induced thermotherapy in the treatment of local recurrences and skin secondaries of breast cancer pp. 15-15(1) Authors: Ismail M.S.; Torsten U.; Philipp C.; Weitzel H.; Berlien H.-P.
Diagnostic problems of evaluating bone metastasis from breast cancer by proliferative activity: Comparison of findings between bone scintigraphy and MRI and their relationship to prognosis pp. 15-15(1) Authors: Nishimura R.; Nagao K.; Miyayama H.; Yasunaga T.
Changes in biochemical markers of bone turnover in breast cancer patients with bone metastases pp. 15-16(2) Authors: Vrbanec D.; Belev B.
A combination therapy with mitomycin-C, etoposide, doxifluridine and medroxyprogesterone acetate as second-line therapy for advanced breast cancer pp. 16-16(1) Authors: Osaki A.; Ohi Y.; Hirai T.; Toge T.
Mastectomy in addition to chemotherapy improves relapse free survival in women with locally advanced breast cancer pp. 16-16(1) Authors: Bajic N.; Scepanovic D.
Improving results in the treatment of locally advanced T4 breast cancer pp. 16-16(1) Authors: Ionta M.T.; Nicolosi M.P.; Murru R.; Mascia M.G.; Scanu A.; Massidda B.
Continuous infusion of adriamycin + cyclophosphamide + 5-fluorouracil in disseminated breast cancer pp. 16-16(1) Authors: Karasyeva V.; Zharkova O.; Promzeleva N.
Sonomammography an objective tool for assessment of chemotherapeutic response in locally advanced breast cancer pp. 16-17(2) Authors: Kumar A.; Agrawal S.; Shukla R.C.
Activity of chemotherapy based on Navelbine in pre-treated metastatic breast cancer patients pp. 17-17(1) Authors: Leusik A.; Khodina T.; Zhavrid E.
Vinorelbine (VNR) + 5-fluorouracil continuous infusion (5-FU c.i.) in pretreated advanced breast cancer - Adria Medica Group pp. 17-17(1) Authors: Cobelli S.; Scanni A.; Battelli T.; Pisone A.; Frontini L.; Di Lullo L.; Mattioli R.
Treatment of liver-metastases in patients with breast cancer pp. 17-17(1) Authors: Jager W.; Wieland G.; Lang N.
Primary medical treatment of locally advanced disease reveals causes of failure of adjuvant chemotherapy pp. 17-17(1) Author: Johnson A.
Comparative study of taxol (T) and Cisplatin(C) versus Taxotere (Tx) and vinorelbine (V) in metastatic breast cancer (MBC). Preliminary results pp. 17-18(2) Authors: Rodriiguez M.R.; Mata J.G.; Firvida J.L.; Salgado M.
Liver metastases from breast cancer - Clinical feature and treatment pp. 18-18(1) Authors: Masuda N.; Yayoi E.; Nakano Y.; Monden T.; Okamura J.
New drugs in breast cancer pp. 18-18(1) Author: Mauriac L.
EORTC 10941; Final results of a phase II study of liarozole fumarate in patients with metastatic breast cancer pp. 18-18(1) Authors: Klijn J.; Hamilton A.; Beex L.; Mauriac L.; Paridaens R.; Roy J.A.; Awada A.; Van Vreckem A.; Palmer P.; Piccart M.
Gamma linolenic acid with tamoxifen as primary therapy in breast cancer pp. 18-19(2) Authors: Kenny F.S.; Pinder S.; Ellis I.O.; Bryce R.P.; Hartley J.; Robertson J.F.R.
Breast cancer clinical trials with Faslodex - A new class of antioestrogen pp. 19-19(1) Authors: Howell A.; Osborne C.K.; Morris C.Q.; Dimery I.
Combination of antimetastatic and antiproliferative therapies in the treatment of experimental breast cancer pp. 19-19(1) Authors: Setyono-Han B.; Foekens J.A.; Wood J.; Klijn J.G.M.
Influence of amifostine (A) on the toxicity and pharmacokinetics (PK) of docetaxel (D) in breast cancer patients: An EORTC-IDBBC study pp. 19-19(1) Authors: de Valeriola D.; Awada A.; Van Vreckem A.; Habboubi N.; Riva A.; Piccart M.
EORTC 10968; Phase I study of CaelyxTM at a six week interval in patients with metastatic breast cancer pp. 19-19(1) Authors: Hamilton A.; Coleman R.; Mauriac L.; Awada A.; Piccart M.; Van Vreckem A.; Bruning P.
Plasma thrombospondin (pTSP) in early and advanced breast cancer pp. 19-20(2) Authors: Byrne G.J.; Hayden K.E.; Aggarawal R.; Howell A.; Bundred N.J.
The 'ZEBRA' study: An open randomised trial of 'zoladex' vs CMF as adjuvant therapy in the management of node positive stage II breast cancer in pre/peri-menopausal women aged 50 years or less pp. 20-20(1) Authors: Kaufmann M.; Jonat W.
First interim results of an ongoing study comparing the GNRH-agonist leuprorelinacetate and CMF as adjuvant treatment in premenopausal breast cancer pp. 20-20(1)
Effect of dietary GLA +/- tamoxifen on growth and ER in a human breast cancer xenograft model pp. 20-20(1) Authors: Kenny F.S.; Gee J.M.; Nicholson R.I.; Morris T.; Watson S.; Bryce R.P.; Hartley J.; Robertson J.F.R.
Prognostic value of cathepsin D expression and association with histomorphological subtypes in breast cancer pp. 20-21(2) Authors: Kainz C.; Losch A.; Tempfer C.C.; Hefler L.; Kucera E.E.; Sliutz G.
A phase II study of a potent and selective aromatase inhibitor, anastrozole (ZD-1033), in Japanese postmenopausal women with advanced/recurrent breast cancer pp. 21-21(1) Author: Koyama H.
The increasing of effect after discontinuation of the treatment with Taxotere in patients with breast cancer pp. 21-21(1) Authors: Gorbounova V.; Borisova T.; Orel N.
Intratumoral focused chemotherapy with cisplatin/epinephrine injectable gel for palliative treatment of metastatic breast cancer pp. 21-21(1)
EORTC-IDBBC (Investigational Drug Branch for Breast Cancer): Seven years of active European collaboration pp. 21-21(1) Authors: Awada A.; Cufer T.; Beex L.; Coleman R.; Paridaens R.; Bruning P.; Klijn J.; Nooij M.; Mauriac L.; Van Vreckem A.; Biganzoli L.; Piccart M.J.
Topical use of Miltex(R) in patients with breast cancer's cutaneous manifestations pp. 21-22(2) Authors: Kasianenko I.V.; Zinevich O.K.; Pivnjuk V.M.; Lisitsa A.M.; Drozdov V.M.
Antitumor effects of 22-oxa-calcitriol on MDA-MB-231 tumors in athymic mice pp. 22-22(1) Authors: Matsumoto H.; Iino Y.; Koibuchi Y.; Maemura M.; Horiguchi J.; Takei H.; Nagaoka H.; Ninomiya J.; Yokoe T.; Morishita Y.
Efficiency of using the intensive regimen of chemotherapy with high doses of 5-fluorouracil in treating patients having breast cancer pp. 22-22(1) Authors: Slonimskaya E.M.; Kolesnikov S.V.; Kanasyova V.V.; Garbukov E.Y.; Shagiakhmetova R.A.
Outcome in patients with advanced breast cancer treated with anastrozole following loss of reponse to tamoxifen and megestrol acetate pp. 22-22(1) Authors: Mihaimeed F.; Kelleher S.M.; Parbhoo S.
Intratumoral therapy with VRCTC-310 for refractory skin metastatic breast cancer. Preliminary report pp. 22-22(1) Authors: Costa L.; Miles H.; Araujo C.; Villarrubia V.
Chemoprevention of breast cancer - An update pp. 23-23(1) Author: Cuzick J.
Geographic distribution within the Netherlands of families with specific mutations in BRCA1 and BRCA2 pp. 23-23(1) Authors: Verhoog L.; Meijers-Heijboer E.J.; Wagner A.; Seynaeve C.; van den Ouweland A.M.W.; Halley D.J.J.; Devilee P.; Klijn J.G.M.
Mutations in the BRCA1 and BRCA2 genes: Uptake of presymptomatic DNA test, preventive choices and breast cancer risk after prophylactic mastectomy pp. 23-23(1) Authors: Meijers-Heijboer H.; Verhoog L.; Brekelmans C.; van Geel B.; Seynaeve C.; Wagner A.; van den Ouweland A.; Frets P.; Niermeijer M.; Klijn J.
Ethnicity, diet, and mammographic density patterns pp. 23-23(1) Authors: Maskarinec G.; Meng L.; Shumay D.; Ursin G.
The risk of breast cancer in women with affective or neurotic disorders pp. 23-24(2) Authors: Hjerl K.; Olsen E.; Keiding N.; Mortensen P.B.; Jorgensen T.
Breast cancer and risk factors: A comparative study between a low and a high risk population pp. 24-24(1) Authors: Straccia A.T.; Vlastos G.; Mock P.; Huang J.; Li H.W.; Campana A.; Morabia A.
Worse survival of patients with endometrial cancer following tamoxifen treatment for breast cancer: A study with 309 second tumors pp. 24-24(1) Authors: Bergman L.; Beelen M.L.R.; Gallee M.P.W.; Benraadt J.; van Leeuwen F.E.
Serum and nipple aspirate levels of vitamin A and vitamin E and lack of an association with breast cancer pp. 24-24(1) Authors: Hargreaves D.F.; Sinha G.; Richmond K.L.; Newland P.; Potten C.S.; Bundred N.J.
Individual breast cancer risk in premenopausal women pp. 24-24(1) Authors: de Souza R.M.; Lazzaron A.R.; Defferrari R.; Borba A.A.; Scherer L.; Frasson A.L.
Individual breast cancer risk assessement in postmenopausal women pp. 24-25(2) Authors: de Souza R.M.; Lazzaron A.R.; Defferrari R.; Borba A.A.; Scherer L.; Frasson A.L.
First-degree family history and breast cancer pp. 25-25(1) Authors: de Souza R.M.; Lazzaron A.R.; Defferrari R.; Borba A.A.; Scherer L.; Frasson A.L.
Second-degree family history and breast cancer pp. 25-25(1) Authors: de Souza R.M.; Lazzaron A.R.; Defferrari R.; Borba A.A.; Scherer L.; Frasson A.L.
A rigorus follow-up study is necessary to precisely estimate the effect of adjuvant therapy in early breast cancer pp. 25-25(1) Authors: Nomura Y.; Takayama T.; Takenaka Y.
Breast reconstruction by TRAM flap: Technical options pp. 25-26(2) Author: Santi P.L.
Immediate reconstruction in breast cancer surgery. Three hundred consecutive cases using prostheses and flaps pp. 26-26(1) Authors: Montanari M.; Sidoli O.
Aesthetic results of the breast cancer conservative treatment in the lower quadrants pp. 26-26(1) Authors: Calabrese C.; Distante V.; Nannelli A.; Simoncini R.; Cataliotti L.
Early experience of ultraconservative skin saving mastectomy and immediate breast and areolar reconstruction pp. 26-26(1) Authors: Rainsbury R.M.; Peyser P.M.; Abel A.; Straker V.
QU.A.RT. versus SSM + TRAM flap immediate breast reconstruction in T2 > 3 cm n0-1 m0 breast cancer: Preliminary data pp. 26-26(1) Authors: D'Aiuto G.; Gherardini G.; Thomas R.; Cortino R.G.; D'Aiuto M.; Elmo M.; Frezza P.; Botti G.; Di Bonito M.
Long term cosmetic results of immediate breast reconstruction by implants pp. 27-27(1) Authors: Vlastos G.; Fitoussi A.; Mosseri D.; Bourgeois D.; Clough K.B.
Breast cancer - A new technique of reconstruction pp. 27-27(1) Authors: Nemsadze G.; Gogoberidze Z.; Katashvili D.; Dzagnidze I.; Sikharulidze G.
Breast reconstruction with free microvascular TRAM flap pp. 27-27(1) Authors: von Smitten K.; Nieminen T.; Asko-Seljavaara S.; Suominen E.
Morbidity following immediate breast reconstruction (IBR) after mastectomy pp. 27-27(1) Authors: Venizelos B.; Chan P.; Lambah A.; Chiarello M.M.; Chetty U.; Dixon J.M.
After mastectomy: Breast reconstruction. The nurse's counselling role pp. 27-27(1) Author: Ferrario R.
Onco-plastic concept (tumor specific immediate reconstruction - TSIR) in breast cancer surgery pp. 28-28(1) Authors: Crnogorac N.; Djurovic M.; Pavlicic M.; Vujadinovic O.
Return of touch sensibility in the breast after immediate free microvascular tram reconstruction pp. 28-28(1) Authors: Korvenoja M.-L.; von Smitten K.; Asko-Seljavaara S.
Breast reconstruction (BR) in breast cancer (BC) patients pp. 28-28(1) Authors: Blokhin S.N.; Portnoj S.M.; Lactionov K.P.; Akopian A.S.; Barcanov A.I.; Coptiaeva I.V.; Melikhova E.A.; Dydykina I.Y.; Sporycheva L.N.
Use of mesh to repair the submuscolar pocket in breast reconstruction: A new possible technique pp. 28-28(1) Authors: Regolo L.; Giuntini T.; Galassi G.; Amanti C.
Reconstructive surgery using titanium plate for osseous defect after wide resection of chest wall for locoregional recurrence of breast cancer pp. 28-28(1) Authors: Noda S.; Kanasugi K.; Ohtsuka T.; Komoriyama H.; Tanaka I.; Ikezawa H.; Hagiwara M.; Hiekata T.; Uji T.
Full thickness resection of chestwall for local recurrence of breast cancer pp. 29-29(1) Authors: Tjalma W.; Van Schil P.; Verbist A.M.; Buytaert P.; van Dam P.
Immediate breast reconstruction in breast cancer pp. 29-29(1) Authors: Demidov V.P.; Pak D.D.; Evtiaghin V.V.; Yermakov A.V.
Abdominal wall closure after TRAM-use of large mesh - Experience with 50 patients pp. 29-29(1) Authors: Moscona R.; Klein R.; Toledano H.
Developing new methods of surgical management of breast cancer followed by plastic pp. 29-29(1) Authors: Esenkulov A.E.; Esenkulova S.A.; Mukashev A.
Preoperative serum VEGF in primary breast cancer patients - Its relation with oestrogen receptor status and cancer type pp. 29-29(1) Authors: Heer K.; Kumar H.; Speirs V.; Drew P.J.; Fox N.J.; Carleton J.P.; Monson R.T.J.; Kerin M.
Prognostic impact of HER-2/neu gene copy number determination by fluorescence in situ hybridisation (FISH) versus immunohistochemically detected overexpression in node positive primary breast cancer pp. 30-30(1)
Lack of correlation between c-erbB-2 overexpression and the effect of dose-intensification of adjuvant chemotherapy in high-risk breast cancer patients pp. 30-30(1) Authors: Thomssen C.; Untch M.; Konecny G.; Lebeau A.; Dettmar P.; Sattler D.; Kuhn W.; Kahlert S.; Hepp H.; Graeff H.; Janicke F.
A study of molecular markers with potential prognostic and predictive value (c-erb b-2, p53, cyclin D1, MIB1, ER and PgR) in locally advanced breast cancer treated with neo-adjuvant dose intensive chemotherapy in an EORTC-NCIC-SAKK randomized phase I pp. 30-30(1) Authors: Bonnefoi H.; Diebold-Berger S.; Hamilton A.; van de Vijver M.; MacGrogan G.; Shepherd L.; Amaral N.; Raoust I.; Drijkoningen M.; Therasse P.; Piccart M.
Heregulin and doxorubicin activate a p53 dependent pathway in cancer cells whereas taxol depends on activation of the MAP kinase pathway pp. 30-30(1) Authors: Bacus S.; Kiffmeyer B.; Gudkov A.; Keyomarsi K.
Accumulation of p53 is associated with response to pre-operative chemotherapy in primary operable breast cancer pp. 31-31(1)
PS2 helps to predict responders to tamoxifen therapy in patients with recurrent breast cancer pp. 31-31(1) Authors: Look M.P.; Meijer-van Gelder M.E.; Klijn J.G.M.; Foekens J.A.
Dietary factors and breast cancer pp. 31-31(1) Author: Bingham S.
Psychological factors in the use of complementary therapies pp. 31-31(1) Author: Steele S.
Contra: Risks and benefits of hormone replacement therapy pp. 35-35(1) Authors: Pecorelli S.; Fallo L.
Pro: Risks and benefits of hormone replacement therapy pp. 35-35(1) Author: Raju K.S.
Lymphatic mapping and sentinel lymphadenectomy pp. 36-36(1) Author: Giuliano A.E.
FDG-PET in breast cancer staging and biological characterization pp. 36-36(1) Authors: Bombardieri E.; Crippa F.; Greco M.; Salvadori B.
Breast conservation without axillary dissection pp. 36-36(1) Authors: Galimberti V.; Zurrida S.
Predictors of axillary lymph node metastases pp. 36-36(1) Author: van de Vijver M.J.
Expression of the c-erbB-4/her-4 growth factor receptor in breast cancer pp. 37-37(1) Authors: Gullick W.J.; Srinivasan R.; Gillett C.; Barnes D.
Tumour suppressor genes in breast cancer pp. 37-37(1) Author: Borresen-Dale A.-L.
The immune response to breast cancer pp. 37-37(1) Authors: Scholl S.M.; Baron C.; Salamaro J.; Beuzeboc P.; Deneux L.; Beuvon F.; Pouillart P.
Inactivation of E-cadherin in breast cancer pp. 37-37(1) Author: Van de Vijver M.J.
Long-term follow-up of the first breast conservation trial (Guy's Wide Excision Study) pp. 37-38(2) Author: Fentiman I.S.
NSABP Protocol B-06: A randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer - Results after 15 years of follow-up pp. 38-38(1) Authors: Wickerham D.L.; Anderson S.A.; Fisher B.; Margolese R.; Mamounas T.; Wolmark N.
The Milan experience in surgical strategies for early breast cancer (overview on prospective trials with latest end-results) pp. 38-38(1) Author: Salvadori B.
The impact of local control in early breast cancer. Update of the EORTC trials pp. 38-38(1)
Why do cancer doctors burn out and can it be prevented? pp. 38-39(2)
The impact of quality of life (QL) scores on survival in patients with metastatic breast cancer (MBC) pp. 39-39(1)
Treatment decision making in breast cancer: The use of multimedia pp. 39-39(1) Authors: Molenaar S.; Sprangers M.A.G.; Rutgers E.J.T.; Postma-Schuit F.C.E.; Oosterveld P.; de Haes J.C.J.M.
Needs for care in breast cancer patients pp. 39-39(1) Authors: de Haes J.C.J.M.; Molenaar S.
Expanding our knowledge of breast cancer biology: Will it impact on patient management? pp. 39-39(1) Author: Piccart M.J.
New challenges in the medical treatment of breast cancer pp. 40-40(1) Author: Gianni L.
Long term survival of patients treated with neoadjuvant chemotherapy for operable breast tumors: Results of a randomized trial with a 10 year-follow-up pp. 40-40(1)
Randomised trial of long-term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone in patients with early-stage breast cancer treated with breast-conserving surgery pp. 40-40(1) Authors: Dalberg K.; Johansson H.; Johansson U.; Rutqvist L.E.
Adjuvant CMF +/- tamoxifen (TAM) in premonopausal high-risk patients (PHRPs) with early breast cancer pp. 40-40(1)
Randomised adjuvant trial comparing two dose intensities of epirubicin and cyclophosphamide (EC) in high-risk breast cancer pp. 41-41(1) Authors: Konecny G.; Thomssen C.; Untch M.; Kahlert S.; Kuhn W.; Sattler D.; Piche E.; Lebeau A.; Dettmar P.; Graeff H.; Janicke F.
Comparison of 3 versus 6 cycles CMF in node positive breast cancer patients based on 10 years follow-up pp. 41-41(1)
Doxorubicin (A) followed by docetaxel (T) versus doxorubicin + docetaxel (AT) in the adjuvant treatment of breast cancer (BC) pp. 41-41(1) Authors: Di Leo A.; Crown J.; Nogaret L.M.; Duffy K.; Bartholomeus S.; Dolci S.; Rowan S.; O'Higgins N.; Riva A.; Piccart M.J.
Doxorubicin vs CMF in the adjuvant tratment of high risk breast cancer pp. 41-41(1) Authors: Semiglazov V.F.; Bozhok A.A.; Ivanova O.A.; Iranov V.G.; Golubeva O.M.
A randomized phase III trial of adjuvant endocrine therapy with tamoxifen for one year (TAM1) vs tamoxifen for two years (TAM2) in postmenopausal high risk patients with estrogen receptor positive or estrogen receptor unknown breast cancer. A DBCG st pp. 41-42(2)
Adjuvant Goserelin depot in premenopausal women with early breast cancer: Ovarian function, bone mineral density and survival. Preliminary data pp. 42-42(1) Authors: De Matteis A.; D'Aiut G.; Landi G.; Nuzzo F.; Labonia V.; Montedoro D.; Rossi E.; Capasso I.; Pizzoruss M.
Ovarian toxicity of breast cancer chemotherapy pp. 42-42(1) Authors: Weber B.; Luporsi E.
Early treatment of metastatic breast cancer patients after increase of CEA and CA15-3 serum levels pp. 42-42(1) Authors: Kramer S.; Jager W.; Lang N.
Docetaxel toxicity and activity in anthracycline-pretreated metastatic breast cancer (MBC) pp. 42-42(1) Authors: Milella M.; Vaccaro A.; Ferraresi V.; D'Ottavio A.M.; Papaldo P.; Nistico C.; Marsella A.; Thorel M.F.; Carpino A.; Cercato M.C.; Terzoli E.; Cognetti F.
Final results of a phase II study of Taxotere (docetaxel, D), doxorubicin (Dx) and cyclophosphamide (CTX) (TAC) in the treatment of metastatic breast cancer (MBC) pp. 43-43(1) Authors: Nabholtz J.-M.; Mackey J.R.; Smylie M.; Paterson A.; Noel D.; Al-Twelgeri T.; Janowska-Wieczorek A.; Delome F.; Riva A.
Serum tumor markers in metastatic breast cancer comparative study between CEA, CA-15.3 and MCA pp. 43-43(1) Authors: Carneiro C.; Costa L.; Melo M.; Quintela A.; Miranda I.; Jorge M.; Pina F.; Gouveia A.; Miguel M.J.; Costa E.B.
Meta-analysis of dose intensity in breast cancer neoadjuvant chemotherapy (1997 update) pp. 43-43(1) Authors: Shparyk Y.; Bilynsky B.
Vinorelbine in combination with 5-fluorouracil in metastatic breast cancer (MBC) pp. 43-43(1) Authors: Donadio M.; Bertetto O.; Comandone A.; Manzin E.; Mistrangelo M.; Seles E.; Bumma C.
Early breast cancer: How long should tamoxifen continue? pp. 43-44(2) Authors: Davies C.; Monaghan H.; Peto R.
Dose-dense weekly docetaxel and CBDCA in adriamycin-resistant metastatic breast cancer (MBC) pp. 44-44(1) Authors: Salimi M.; Mir M.R.
Hormonotherapy with goserelin depot after adjuvant chemotherapy in premenopausal women with early breast cancer: Is there any benefit? pp. 44-44(1) Authors: De Matteis A.; Montedoro D.; Nuzzo F.; Landi G.; Labonia V.; Rossi E.; D'Aiuto G.
Second- and third-line treatment of metastatic breast cancer with gemcitabine pp. 44-44(1) Authors: Brodowicz T.; Moslinger R.; Herscovici V.; Vaclavik I.; Wiltschke C.; Kubista E.; Zielinski C.
Mitomycin (M), epirubicin (E) and vinorelbine (V) first-line chemotherapy for metastatic breast cancer (MBC). A feasibility study pp. 44-44(1) Authors: Neri A.; Guarnieri A.; Tucci E.; Pepi F.; Mazzocchi B.; Algeri R.
Sequential or simultaneous chemo-radiotherapy in operable breast cancer. A French multicentric phase III study - State of inclusions pp. 44-45(2) Authors: Nogues C.; Garbay J.-R.; Serin D.; Graic Y.; Leduc B.; Demange L.; Lucas V.; Combe M.; Castera D.; Rouesse J.
Does the administration of anthracyclines affect human tumour blood flow? pp. 45-45(1) Authors: Goodchild K.; Hill S.; Makris A.; Chaplin D.
Ocular toxicity related to tamoxifen therapy pp. 45-45(1) Authors: Veselinovic S.; Filipovic S.; Veselinovic D.; Djordjevic L.; Rancic Z.
Breast cancer patients treated without axillary surgery: Clinical implications and biological analysis pp. 45-45(1) Author: Greco M.
Preoperative MRI does not influence the amount of breast tissue excised in conservative cancer surgery pp. 45-46(2) Authors: Douek M.; Vaidya J.; Davidson T.; Lakhani S.R.; Hall-Craggs M.A.; Baum M.; Taylor I.
Preoperative assessment of axillary lymph-node involvement in small breast cancers. Analysis of 893 cases pp. 46-46(1) Authors: Cutuli B.; Velten M.; Rodier J.F.; Quetin P.; Jaeck D.; Renaud R.; Duperoux G.
Conservation surgery and specialist treatment pp. 46-46(1) Authors: Kingsmore D.B.; Hole D.; Gillis C.R.; George W.D.
Are risk factors for local and distant recurrence following breast-conserving therapy for early breast cancer similar to those following mastectomy? pp. 46-46(1) Authors: Voogd A.C.; Nielsen M.; Peterse J.L.; Blichert-Toft M.; Bartelink H.; van Tienhoven G.; Andersen K.W.; Sylvester R.; van Dongen J.A.
The characteristics and management of extremely elderly patients with breast cancer pp. 46-46(1) Authors: Makino H.; Sano M.; Sasaki J.; Tanaka O.; Nashimoto A.; Tsutsui M.; Tsuchiya Y.
Axillary surgery in patients with breast cancer being treated by breast conservation: A randomised trial of node sample or axillary clearance pp. 47-47(1) Authors: Chetty U.; Jack W.; Dillon P.; Tyler C.; Prescott R.
Increased risk of tumor recurrence following breast conserving therapy (BCT) in hereditary breast cancer as compared with sporadic breast cancer (BC) pp. 47-47(1) Authors: Seynaeve C.; v.d. Bosch L.C.M.; Brekelmans C.T.M.; Verhoog L.C.; van Geel A.N.; Wagner A.; Meijers E.J.; v.d. Ouweland A.; Klijn J.G.M.
Predicting nodal status in patients with T1 breast cancer pp. 47-47(1) Authors: Harden S.P.; Neal A.; Al-Nasiri N.; Ashley S.; Querci della Rovere G.
The effect of immediate volume replacement with latissimus dorsi miniflaps on the outcome of breast-conserving surgery pp. 47-47(1) Authors: Rainsbury R.M.; Paramanathan N.; Straker V.; Abel A.
A prospective study of intra-operative localisation of sentinel lymph node in patients with breast cancer using dye technique pp. 47-47(1) Authors: El Grammal M.; Paterson A.; Jones H.; Stepp K.; Hofmeyr C.; Brand J.
Magnetic resonance guided breast surgery pp. 48-48(1) Authors: Vaughan N.; Gould S.; Lamb G.; Lauro A.; Ojo A.; Lomax D.; Gedroyc W.; Darzi A.
Management of non-palpable mammographic abnormalities: ABBI excision vs core biopsy pp. 48-48(1) Authors: Menon M.; Chatterjee S.; Drew P.J.; Imrie M.J.; Fox J.N.; Carleton P.J.; Monson J.R.T.; Kerin M.J.
Accuracy of endoscopic axillary lymph node dissection in breast cancer patients pp. 48-48(1) Authors: Kuhn T.; Santjohanser C.; Koretz K.; Kreienberg R.
The specialist treatment of the axilla pp. 48-48(1) Authors: Kingsmore D.B.; Hole D.; Gillis C.R.; George W.D.
The relationship between margins of resection and the risk of local recurrence after breast conserving therapy pp. 48-49(2) Authors: Distante V.; Simoncini R.; Bianchi S.; Pacini P.; Petrolo A.; Orzalesi L.; Cataliotti L.
Microinvasive carcinoma of the breast: Is axillary lymph node dissection indicated? pp. 49-49(1) Authors: Penault-Llorca F.; Le Bouedec G.; Pomel C.; Feillel V.; Dauplat J.; de Latour M.
Oncologic outcome in patients with breast cancer treated with breast conserving reconstruction pp. 49-49(1) Authors: Noguchi M.; Tsugawa K.; Kawahara F.; Taniya T.; Miwa K.
Prophylactic mastectomy: Patient selection and development of a surgical technique pp. 49-49(1) Authors: Baildam A.D.; Evans D.G.R.; Hopwood P.
Superconservative surgery for early breast cancer: Preliminary results pp. 49-50(2) Authors: Thomas R.; Taddeo F.; Rinaldo M.; Elmo M.; Frezza P.; Losito S.; Labonia V.; D'Aiuto M.; D'Aiuto G.
Preoperative factors influencing complete excision of palpable breast cancer in breast conserving therapy pp. 50-50(1) Authors: Venizelos B.; Chan P.; Greenwood S.; Dillon P.; Dixon J.M.
Dye-guided sentinel lymphadenectomy in clinically node-positive and node-negative breast cancer patients pp. 50-50(1) Authors: Noguchi M.; Tsugawa K.; Kawahara F.; Bando E.; Miwa K.
Do lobular & ductal carcinoma lead to different local recurrence rates after breast conservation? pp. 50-50(1) Authors: Chan H.; Harris L.A.; Greenall J.
Efficacy and significance of sentinel lymph node identification with technetium-99m-labeled tin colloids for breast cancer pp. 50-50(1) Authors: Sato K.; Hiraide H.; Tamaki K.; Ishikawa H.; Yamasaki T.; Uematsu M.; Tamai S.; Kusano S.; Mochizuki H.
Stereotaxic guided excisional biopsy (ABBI(R)) - A new method for precise and minimal invasive breast surgery? pp. 50-51(2) Authors: Kramer S.; Lang N.
A prospective study of sentinel lymph node in patients with breast cancer using a combined technique: Dye and radio-labelled colloid pp. 51-51(1) Authors: El Gammal M.M.; Paterson A.G.; Vivian G.; Hofmeyr C.J.; Stepp K.; Jones H.; Brand J.M.
The frequency of metastases in the interpectoral lymphatic pathway in patients with breast cancer pp. 51-51(1) Authors: Jeziorski A.; Berner A.; Faflik M.
multiple lymphatic drainage pathways in breast cancer and its implication for sentinel lymph node (SLN) biopsy and internal mammary (IM) lymph node biopsy or radiation pp. 51-51(1) Authors: Jeffrey S.; R.L. Birdwell J.; Ikeda D.M.; Cua D.O.; Ansari Y.; Strauss W.
Male breast cancer: A retrospective analysis of patients treated in Trieste, Italy pp. 51-51(1) Authors: Sandri P.; Vidali C.; Milan V.; Trivillin V.; Mustacchi G.
Breast-conserving therapy in case of carcinoma tumours larger than 2 cm with the help of individually adapted oncoplastic operations pp. 51-52(2) Authors: Schondorf N.K.; Dimpfi C.
conservative treatment of stage II breast cancer patients with simultaneous mammoplastic operations pp. 52-52(1) Authors: Ostapenko V.; Pipiriene T.; Valuckas K.
Conservative surgery without radiation for the patients with the negative surgical margin of the early breast cancer - Significance of two stage treatment pp. 52-52(1) Authors: Kimura M.; Koida T.; Yanagita Y.; Ogawa A.; Sugihara S.
A clinical comparative study of adjuvant therapy after breast conserving surgery for early breast cancer pp. 52-52(1) Authors: Tominaga T.; Koyama H.; Nomura Y.; Miura S.; Morimoto T.
Breast conserving operations, frequency of vessels invasion, and disease free survival of the breast cancer T1-2N0-1N0 patients pp. 52-52(1) Authors: Portnoj S.M.; Lactionov K.P.; Barcanov A.I.; Ermilova V.D.; Koptiaeva I.V.; Balakireva G.V.; Akhmetov M.S.
The problem of arm oedema after axillary dissection and/or radiotherapy in breast cancer patients pp. 53-53(1) Authors: Jeziorski A.; Piekarski J.; Berner A.; Berner J.
Prospective randomized study on drainages removal timing in breast cancer surgery pp. 53-53(1) Authors: Amanti C.; Lombardi A.; Antonaci A.; Di Paola M.; Regolo L.
'Lunate flaps': Tissue advancement for parenchymal reconstruction in breast cancer surgery pp. 53-53(1) Author: Baildam A.D.
Neoadjuvant chemotherapy for primary breast cancer - How many breasts are saved? pp. 53-53(1) Authors: Bramley M.D.; Harake J.; Boggis C.R.M.; Howell A.; Bundred N.J.
Skin-sparing mastectomy with immediate TRAM (Transverse rectus abdominis myocutaneous) flap reconstruction pp. 53-53(1) Authors: Chang H.T.; Chen J.S.; Mok K.T.
Arm morbidity in 131 women with small breast tumours (up to 10 mm) who all had level 2 axillary clearance pp. 54-54(1) Authors: Stallard S.; Mallon E.A.; Doughty J.C.; Kingsmore D.; Mallik H.; Hiew L.; Watt C.; George W.D.
Breast sarcoma and carcinosarcoma in the material of Cancer Center-Institute in Warsaw, Poland pp. 54-54(1) Authors: Niwinska A.; Chmielewski R.
Plastic procedures in conservative surgery for breast cancer pp. 54-54(1) Authors: Caruso F.; Marino M.; Mannino F.; Ferrara M.; Castiglione G.; Catalano F.; Petralia G.; Piazza D.
The dominant sentinel node in breast cancer: A new technique pp. 54-54(1) Authors: Chu D.; Grube B.; Ellenhorn J.; Paz B.; Wagman L.
Multifocality in intraductal carcinoma of breast in young Chinese pp. 54-54(1) Authors: Yu J.C.; Hsu M.H.; Liu M.L.; Liu Y.G.; Chang T.M.
Axillary dissection in stage i breast cancer pp. 55-55(1) Authors: Brondi L.A.G.; Stecca J.; Ferro M.C.
Increasing the percentage of breast-conserving surgery for treatment of breast cancer pp. 55-55(1) Authors: Escobedo A.; Benito E.; Azpeitia D.; Prieto L.; Moreno F.; Serra J.M.; Gil M.
Clinical significance of rapid scraping cytology to ensure the cancer free margin in breast conserving surgery pp. 55-55(1) Authors: Miyauchi M.; Yamamoto N.
Morbidity of quadrantectomy vs mastectomy in operable breast cancer pp. 55-55(1) Authors: Nieto A.; Lozano M.; Moro M.T.; Cano A.; Tacuri C.; Cortes-Prieto J.
The place of the sentinel node mapping in the management of breast cancer: Prospective analysis - New aspects pp. 55-55(1) Authors: Makar A.; Melis K.; Van Den Weyngaert D.; Van Leuven L.; Kockx M.; Vandevivere J.; Denis L.
Functional and cosmetic results in breast preserving treatment (BPT) pp. 55-56(2) Authors: Prekajski M.; Dzodic R.; Borojevic N.; Mitrovic L.; Posarac V.; Radovanovic P.
Successes and relapses in breast conserving therapy (bct) in early breast cancer on the base of 17 years own experiences pp. 56-56(1) Authors: Berner J.; Jeziorski A.; Berner A.; Nejc D.
Non-palpable breast lesions pp. 56-56(1) Authors: Sandrini R.; Pollini G.P.; Pellini F.; Rettore L.; Ghandour H.M.; Parise V.; Vecchioni R.
Breast conserving therapy in stage I and II breast cancer pp. 56-56(1) Authors: Rancic Z.; Jeremic M.; Stojiljkovic M.; Pesic M.; Djordjevic N.; Gmijovic D.; Djordjevic L.; Djordjevic M.; Filipovic S.; Veselinovic S.
Surgical treatment of breast carcinoma. A study of 460 cases pp. 56-56(1) Authors: Pricop M.; Daniil C.; Strat L.; Aursulesei D.; Bendescu M.; Cocos M.; Gafencu C.
Quality of life of patients with early stage breast cancer treated with breast conservative surgery and postoperative irradiation pp. 57-57(1) Author: Amichetti M.
The influence of the boost on the cosmetic outcome after breast conserving therapy pp. 57-57(1)
The usefull boost range (UBR) concept judges the ballistic selectivity of electron beams (EB) versus brachytherapy (BT) in the boost techniques of breast conserving therapy pp. 57-57(1) Authors: Van Limbergen E.; Reynders A.; Van den Bogaert W.
The value of post lumpectomy mammogram pp. 57-57(1) Authors: Aref A.; Youssef E.; Washington T.; Segel M.; Grigorian C.; Bongers S.; Bouman D.
EORTC randomised phase III trial 22922/10925 investigating the role of internal mammary chain (IMC) irradiation in stage I-III breast cancer: A quality assurance report on the dummy run pp. 58-58(1)
Is hypofractionated breast radiotherapy a valid treatment option? pp. 58-58(1) Author: Ryan G.
Treatment of Paget's disease of the breast with radiotherapy only pp. 58-58(1) Authors: Christiaens M.R.; Knol J.; Van den Bogaert W.; Van Limbergen E.
Radiosurgery of T1 breast cancer: A dosimetry study pp. 58-58(1) Authors: Formenti C.; Jozsel S.; Parisky G.; Skinner V.; Luxton K.
Variation in normal tissue complication probability with radiation technique in early breast cancer pp. 58-59(2) Authors: Canney P.A.; Sanderson R.; Deehan C.; Wheldon T.
Non-invasive follow-up of the viscoelasticity of the breast skin following radiation therapy pp. 59-59(1) Authors: Gorodetsky R.; Lotan C.; Polyansky I.; Vexler A.; Saunders M.; Piggot K.; Dische S.; Pierce L.; Lichter A.
Effect of radiotherapy in addition to 6 cycles CMF in node positive breast cancer patients pp. 59-59(1)
Neo-adjuvant chemo-radiotherapy for operable breast cancer. Preliminary results of an ongoing phase II study pp. 59-59(1)
Breast cancer in premenopausal women/should mastectomy be recommended? pp. 59-59(1)
Tangential breast irradiation: A comparison between 2D and 3D radiation therapy plans pp. 60-60(1) Authors: Aref A.; Thornton D.; Youssef E.; He T.; Ezzell G.
Intratumoral fluorouracil (5-FU) injectable gel as a potentiator of standard radiotherapy in patients with locally recurrent or advanced breast cancer pp. 60-60(1) Author: Kuske R.
Radiation induced brachial plexopathy in early breast cancer pp. 60-60(1) Authors: Miller N.; Kerr G.R.; Grant R.; Rodger A.; Matheson L.; Kunkler I.
Acute reactions and cosmetic outcome after conservative surgery and adjuvant RT in stage I-II breast cancer pp. 60-60(1) Authors: Valli M.C.; Amadori M.; Asnsghi D.; Catalano G.; Francolini D.C.; De Agostini A.; Meregalli S.; Molteni M.; Palazzi M.; Personeni A.
Intraocular metastases from breast cancer: A retrospective Study of the Breast Cancer North Italian Radiation Therapy Oncology Group pp. 60-61(2) Authors: Amichetti M.; Caffo O.; Minatel E.; Roncadin M.; Panizzoni G.; Balli M.C.; Valli M.; Lozza L.; Zucali R.
Nine years results of breast carcinoma conservative treatment for 295 pTI =< 10 mm N- without adjuvant medical treatment pp. 61-61(1)
Is it necessary to check blood counts routinely during definitive radiation therapy for patients with early stage breast cancer? pp. 61-61(1) Authors: Erdmann-Elbinger B.; Schweitzer S.; Schmucking M.; Wendt T.G.
Evaluation of acute local toxicity after postoperative 60 gy to the whole breast in multifocal invasive or in situ ductal breast carcinoma pp. 61-61(1) Authors: Valli M.C.; Bianchi E.; Cagna E.; Bossi A.; Cazzaniga C.D.; Cosentino F.; Prina M.; Scandolaro L.
Long-term (5-10 year) results of combined treatment of breast cancer patients using gamma-neutron therapy pp. 61-61(1) Authors: Smirnova I.; Gulidov I.; Aminov G.
Is the timing of radiotherapy after breast conservation surgery for early stage cancer important? pp. 61-62(2) Authors: Ampil F.; Burton G.; Li B.; Minnard E.; Abreo F.; Person K.; Ethridge L.; Mills G.; Chin H.
Cosmetic evaluation of breast conserving treatment for mammary cancer pp. 62-62(1) Authors: Niwinska A.; Nagadowska M.; Tchorzewska H.
Radiation therapy without boost for breast conserving surgery patients with positive surgical margin or extensive intraductal component pp. 62-62(1) Authors: Miyauchi K.; Takatsuka Y.; Maeura Y.; Alkawa T.; Ymamamoto H.; Nishiyama K.; Inoue T.
Communication skills of oncologists pp. 62-62(1) Author: Fallowfield L.J.
Parcours de femmes: A survey of opinions of French women with cancer; the first step of a pan-European survey in 16 countries pp. 62-62(1) Authors: Serin D.; Pujol H.; Schraub S.; Chevalier H.
UK National Trial assessing the impact of testing for BRCA1/2 breast/ovarian cancer predisposition genes pp. 62-63(2)
Adjuvant chemotherapy for breast cancer patients: Patients' expectations and physicians attitudes pp. 63-63(1) Authors: Kreitler S.; Barak F.; Kovner F.; Inbar M.
Using new technology to disseminate information on breast cancer to women pp. 63-63(1) Author: Maguire P.
A patient model of effective communication for screening mammography pp. 63-63(1) Authors: Fox S.; Reise S.; Stockdale S.
National survey of women with breast cancer in Australia pp. 63-63(1) Authors: Redman S.; Williams P.; Malych P.; Davis C.
Caring About Women and Cancer (CAWAC): The perceptions, experiences and evaluation of cancer care among European women pp. 64-64(1) Author: von Kleist S.
How can survival for women in Scotland with breast cancer be improved? pp. 64-64(1) Authors: Twelves J.C.; Dewar J.; Thomson C.; Gould A.
Breast self examination proficiency in older Black and White women: Efficacy of video self instruction pp. 64-64(1) Author: Wood R.Y.
BSE RAP: The evaluation of a breast self-examination music program, developed to create breast health awareness among teens and their families pp. 64-64(1) Author: Ehmann J.L.
Europa Donna in Italy: Activities and goals pp. 64-65(2) Author: Merzagora F.
Women prefer breast cancer prognosis expressed as chance of cure to 10-year survival pp. 65-65(1) Authors: Vaidya J.S.; Douek M.; Lokare V.G.; Secker-Walker J.; Fallowfield L.; Taylor I.; Baum M.
Endocrine therapy in breast cancer: A nurse education package pp. 65-65(1) Authors: Denton S.; Gledhill J.; Lee L.; Lynn J.; Ferrario R.
Bottle-necks in Dutch breast cancer care pp. 65-65(1) Authors: Taselaar-Benes E.; Postma-Schuit F.C.E.; Buckens K.
Nurses' role in breast cancer control in a multinational community pp. 65-66(2) Authors: Thomas R.; Bryce J.; Capasso I.; De Falco F.; Cortino G.; Melucci M.; D'Aiuto M.; D'Aiuto G.
The Canadian Breast Cancer Initiative pp. 66-66(1) Authors: Mathieu B.A.; Bouchard L.F.; Inhaber M.P.H.S.; Mickelson P.; Parboosingh J.
Breast cancer: The nurse's role in genetic counselling pp. 66-66(1) Author: Ferrario R.
Knowledge and beliefs about breast cancer prevention in an unselected female Italian population pp. 66-66(1) Authors: Biamonte R.; Robbiati S.F.; Caffo O.; Tata F.; Sequi I.; Filippelli G.; Rovito A.; Liguori V.; Conforti S.; Palazzo S.
Patients' perceptions of routine follow-up after treatment for breast cancer and nurse-led clinics pp. 66-66(1) Authors: Pennery E.; Mallett J.; Corner J.; Gui G.
Promoting healthy women pp. 66-67(2) Authors: Lewis M.; DiMaria S.
The structuring of a course of breat self-examination considering oncological, psychological and sociocultural aspects pp. 67-67(1) Authors: Chiechi L.M.; Epifani S.; Lombardi T.
A pathway of care to clinical effectiveness and service efficiency pp. 67-67(1) Authors: McIlvenny C.; Harrison J.; Durning P.; Morris E.
Europa Donna Italian Forum: Results of a survey among the breast cancer associations pp. 67-67(1)
Use of prevention modalities for breast cancer: A survey on 3620 self-administered questionnaires pp. 67-67(1) Authors: Caffo O.; Robbiati S.F.; Brugnara S.; Tata F.; Sequi I.; Serrano P.; Biamonte R.
Care across the continuum - The Breast Care Nurse in Australia pp. 67-68(2) Author: Lewis M.
Genetic counseling: The reality of the Italian associations against breast cancer pp. 68-68(1)
New perspectives on screening, quality assurance and prevention pp. 68-68(1)
Performance issues in detection and diagnosis pp. 68-68(1) Author: Perry N.
'Blind' review of interval breast cancers pp. 68-68(1) Authors: de Rijke J.M.; Schouten L.J.; Schreutelkamp J.L.; Jochem I.; Verbeek A.L.M.
Colour and power Doppler in the differential diagnosis of breast tumours: Correlation with microvessel density and blood vessel counts pp. 68-69(2) Authors: Tehl W.L.; Evans A.J.; Wilson A.R.M.; Denley H.E.; Pinder S.E.; Ellis I.O.
Preoperative identification of node negative axillary lymph nodes in breast cancer by highly significant electron beam computertomography (EBC) pp. 69-69(1) Authors: Smola M.G.; Kriegl D.; Promberger H.; Kronberger L.; Raith J.; Groll R.; Cerwenka H.; Kern R.; Thalhammer M.; Hinkel W.; Preissegger K.H.
99mTc-scintimammography in the diagnosis of non-palpable breast lesions in relation to the mammographical probabilities of malignancy and microcalcifications pp. 69-69(1) Authors: Carril J.M.; Uriarte I.; Quirce R.; Montero A.; Vallina N.; Vega A.; Hernandez A.
99mTc-MIBI scintimammography (SM) in 300 patients with breast masses: Correlation with tumor proliferative activity pp. 69-69(1) Authors: Pasqualoni R.; Tofani A.; Sciuto R.; Semprebene A.; Festa A.; Ferraironi A.; Botti C.; Mottolese M.; Benevolo M.; Maini C.L.
MR imaging in the preoperative staging of breast carcinoma: Useful or riskful? pp. 70-70(1) Authors: Van Goethem M.; Dykmans L.; Buytaert P.; van Dam P.; De Schepper A.
Axillary staging of T1-T2 breast cancer pp. 70-70(1)
A prospective assessment of magnetic resonance mammography (MRM) with conventional triple assessment in symptomatic breast disease pp. 70-70(1) Authors: Chatterjee S.; Menon M.; Drew J.P.; Fox N.J.; Carleton J.P.; Turnbull L.; Read J.; Monson R.T.J.; Kerin J.M.
Palpable breast tumors: Preoperative determination of histology and receptor status pp. 70-70(1) Authors: Cerwenka H.; Hoff M.; Rosanelli G.; Hauser H.; Thalhammer M.; Kronberger L.; Klimpfinger M.; Smola M.G.
Ultrasound guided core biopsy of suspicious mammographic calcifications using high frequency and power Doppler ultrasound pp. 70-71(2) Authors: Teh W.L.; Burrell H.; Evans A.J.; Wilson A.R.M.; Pinder S.E.; Ellis I.O.; Blamey R.
Pre-operative detection of breast cancer multicentricity with MRI pp. 71-71(1) Authors: Douek M.; Vaidya J.; Davidson T.; Lakhani S.R.; Hall-Crag M.A.; Blanchard K.; Baum M.; Taylor I.
Prediction of axillary lymphatic node status in primary breast cancer - Comparison between positron emission tomography (PET) and sentinel-node biopsy pp. 71-71(1) Authors: Santjohanser C.; Kuhn T.; Mobus V.; Maidel K.; Horster T.; Diederichs C.; Truger K.; Koretz K.; Bohm W.; Reske S.N.; Kreienberg R.
The value of high-frequency ultrasound guided core-cut biopsy of breast tumors pp. 71-71(1) Authors: Albert U.-S.; Duda V.F.; Schulz K.-D.
The value of electron beam computertomography in the analysis of breast lesions and lymphnodemetastasis pp. 71-72(2) Authors: Kriegl D.; Smola G.M.; Kronberger L.; Raith J.; Groell R.; Cerwenka M.; Hinkel W.; Rienmueller R.
Advanced breast biopsy instrumentation (ABBI): Initial experience pp. 72-72(1) Authors: Nogaret J.M.; Hertens D.; Veys I.; Coibion M.; Dagnelie J.; Mattheiem W.
Tumor density and malignant characteristics on mammography in the evaluation of tumorresponse in patients treated with preoperative chemotherapy pp. 72-72(1) Authors: Zonderland H.M.; Elkhuizen P.H.M.; van Slooten H.J.; Hermans J.; van de Velde C.J.H.
A new scoring system to evaluate the malignancy risk in mammographic microcalcifications pp. 72-72(1) Authors: Kinget K.; Naudts P.; Hansen K.; Pauwels E.
FNA to core biopsy - A need for change? pp. 72-72(1) Authors: Flanagan F.; Keogh C.; Laird O.; Dowling M.; Ennis J.T.
High resolution computed tomography imaging is useful for the detection of the intraductal tumor spread in breast cancer pp. 72-73(2) Authors: Kobayashi N.; Iwase K.; Takahashi M.; Mizoguchi J.; Inagaki A.; Jimbo S.; Yamamoto H.; Asano Y.; Furusawa K.; Miura K.
Accuracy of dynamic contrast-enhanced MR imaging in patients with indeterminate mammograms pp. 73-73(1) Authors: Imbriaco M.; Sodano A.; Riccardi A.; Del Vecchio S.; Panza M.; Limite G.; Pace U.; Forestieri P.; Petrella M.; Salvatore G.
MR imaging of the breast in patients with mammographically ill-defined breast cancer pp. 73-73(1) Authors: Sawai Y.; Kuroda C.; Kasugai T.; Koyama H.
Detection by means of RT-PCR of micrometastases in the peripheral blood, bone marrow and leukapheresis products in women with breast cancer, selected for high-dose chemotherapy and peripheral blood progenitor cell transplantation pp. 73-73(1) Authors: Merla G.; Papa S.; Aicta M.; Tartarone A.; Murgo R.; Seripa D.; Di Giorgio G.; Lelli G.; Fazio V.M.
99mTc-MIBI breast scintigraphy using a dedicated nuclear mammograph pp. 73-74(2) Authors: Semprebene A.; de Notaristefani F.; Tofani A.; Sciuto R.; Rea S.; Malatesta T.; Frezza F.; Botti C.; Natali P.G.; Maini C.L.
(111Indium-DTPA-D-Phe) octreotide scintigraphy in the diagnostic assessment of palpable breast lumps pp. 74-74(1) Authors: Parker S.J.; Barker C.P.G.; McLeod M.A.
p43 expression on lymphocytes - A marker for early breast cancer in patients with nonpalpable mammographic finding pp. 74-74(1) Authors: Auerbach L.; Hellan M.; Stierer M.; Rosen A.C.; Ausch C.; Obwegeser R.; Kubista E.; Wolf G.; Rosen H.R.; Panzer S.
Breast metastasis as the first sign of a gastric adenocarcinoma pp. 74-74(1) Author: Baratelli G.M.
Breast cancer care: Does the NHS discriminate against women living in deprived areas? pp. 74-74(1) Authors: Macleod U.; Ross S.; Twelves C.J.; Gillis C.; Watt G.C.M.
Efficiency of cytology for breast cancer without the evidence of malignancy on imaging diagnosis pp. 74-74(1) Authors: Koga T.; Suga K.; Aoyama Y.; Yanaga H.; Yahara T.; Shirouzu K.
Investigation of local blood flow in breast cancer by colour Doppler ultrasonography and immunohistochemistry pp. 75-75(1) Authors: Jimbo S.; Iwase K.; Takahashi M.; Ohtani S.; Tsujimura T.; Inagaki A.; Kobayashi N.; Yamamoto H.; Miura K.
Specialist registrar (SpR) training in fine needle aspiration cytology (FNAC) of breast lumps - Can we do better? pp. 75-75(1) Authors: Cunnick G.H.; Wishart G.C.
Specialist registrar (SpR) training in breast and axillary examination pp. 75-75(1) Authors: Cunnick G.H.; Wishart G.C.
Analysis of serum IgG1 in patients with benign and malignant breast disease pp. 75-75(1) Authors: Kornberger L.; Schauenstein E.; Rabl H.; Steinschifter W.; Estelberger W.; Schauenstein K.; Smola M.
Doppler ultrasound assessment of tumour response pp. 76-76(1) Authors: Robinson T.M.; Halliwell M.; Rayter Z.
Recurrent breast cancer after conservative surgery: Role of contrast enhanced MR imaging pp. 76-76(1) Authors: Grandinetti M.L.; Ferranti F.R.; Saracca E.; Venturo I.; Nistico C.; Botti C.; Crecco M.
Technetium-99m-sestamibi mammoscintigraphy in suspected breast cancer. Radiologic and histologic correlations in 43 surgically treated patients pp. 76-76(1) Authors: Lumachi F.; Zucchetta P.; Cagnato P.; Fontana P.; Polistina F.; Favia G.
The efficacy of ultrasound-guided core needle biopsy for breast mass pp. 76-76(1) Authors: Mitsuyama S.; Anan K.; Ono M.; Toyoshima S.
Comparative study of fat suppressed MR imaging of breast cancer relative to mammography with microcalcification pp. 76-77(2) Authors: Kanasugi K.; Uji T.; Noda S.; Ohtsuka T.; Inada Y.; Komoriyama H.; Tanaka I.; Ikezawa H.; Hagiwara M.; Shinagawa T.
Clinical usefulness of preoperative evaluation of mammary tumours with 99mTc-sestamibi imaging pp. 77-77(1) Authors: Leppanen E.; Tykka H.; Leidenius M.; Roiha M.
Nipple discharge correlation between: clinic, radiology and histology pp. 77-77(1) Authors: Sabadell D.; Garcia M.; Duran A.; Cabaleiro A.; Salicru S.; Xercavins J.
Endocrine cell component in the breast carcinomas pp. 77-77(1) Authors: Akhova O.M.; Galakhin K.A.; Zotikov L.A.; Sclyar S.Y.
Full length analysis of BRCA1 gene in sporadic breast cancer: Detection of common haplotypes and a novel possibly somatic mutation affecting gene translation pp. 77-77(1) Authors: Papa S.; Seripa D.; Merla G.; Gravina C.; Giai M.; Sismondi P.; Serra A.; Saglio G.; Fazio V.M.
Utility of 3D-dynamic magnetic resonance (MR) mammography for detecting the extent of primary tumor and axillary lymph node status of breast cancer patients pp. 78-78(1) Authors: Takeda Y.; Yoshizaki I.; Yanagie H.; Eriguchi M.; Yoshikawa K.
A pathway for a woman: Global approach to breast cancer pp. 78-78(1) Authors: Russo F.M.; Agozzino E.; Molese V.; Thomas R.; Cortino G.; Canfora G.; D'Aiuto G.
In situ trap method for the histological examination of breast cancer (preliminary report) pp. 78-78(1) Authors: Kaise H.; Kusama M.; Nakayama S.; Aoki T.; Koyanagi Y.; Yahata N.; Ohyasiki K.
US guided fine needle aspiration biopsy of non palpable breast lesions pp. 78-78(1) Authors: Santoriello A.; Sciaudone G.; Scarrico A.; Vanore A.; Alberico A.; Canonico S.
Diagnostic significance of nipple discharge for detection of non-palpable breast cancer pp. 78-79(2) Authors: Yayoi E.; Nishi T.; Kisibuchi M.; Yagyu T.; Kawasaki K.; Mori T.; Nakano Y.; Masuda N.
Needle localization breast biopsy for nonpalpable breast lesions pp. 79-79(1) Authors: Nagadowska M.; Wesolowska E.; Pietrow D.; Dziewulska E.; Galezynski J.
Mammographic parenchymal, patterns and breast histology pp. 79-79(1) Authors: Bayar S.; Tukel S.; Kocak S.; Aydintug S.; Sak S.D.
Stereotactic-guided biopsy of occult breast lesions pp. 79-79(1) Authors: Lazzerini M.; Incarbone R.; Bonavina L.
Management of palpable asymmetrical thickening of the breast pp. 79-79(1) Author: Cheung K.L.
Reduction of calcifications and breast cancer: Description of a case pp. 79-80(2) Authors: Armocida C.; Santini D.; Di Pancrazio L.; Ceresatto E.; Negri R.; Criscuolo M.; Gallo E.
The use of technetium-99m methoxyisobutylisonitrile (99mTc-MIBI) breast scintigraphy to evaluate palpable breast masses pp. 80-80(1) Authors: Yeh D.C.; Kao C.H.; Wu C.C.; Liu T.J.
The axilla - What can mammography offer? pp. 80-80(1) Authors: Flanagan F.; Barton P.; Ennis J.T.
Correlation between sestamibi scintigraphy-mammography, mitochondria and neoangiogenesis in breast cancer pp. 80-80(1) Authors: Vanoli C.; Antronaco R.; Giovanella L.; Ceriani L.; Cabrini L.; Torrigiotti G.; Colombo L.
Preliminary results in the scintigraphic and radiosurgical identification of sentinel node (SN) in early stage breast cancer pp. 80-80(1) Authors: Feggi L.; Carcoforo P.; Prandini N.; Sartori A.; Corcione S.; Beccati D.; Candini D.; Donini I.
In situ trap method for the cytological examination of breast cancer (preliminary report) pp. 80-81(2) Authors: Nakayama S.; Kusama M.; Kaise H.; Aoki T.; Koyanagi Y.; Yahata N.; Ohyasiki K.
Update on endocrine approaches in the treatment and prevention of breast cancer pp. 81-81(1) Author: Kaufmann M.
Increased risk of recurrence for patients with EGFR and HER-p185 positive tumours when treated adjuvantly with tamoxifen for one year pp. 81-81(1) Authors: Knoop A.; Bentzen S.; Nielsen M.; Rasmussen B.; Rose C.
Idoxifene antagonism of oestradiol-dependent MCF-7 breast cancer xenograft growth pp. 81-81(1) Authors: Johnston S.R.D.; Dowsett M.; Riddler S.; Jarman M.
Ocular toxicity from standard dose adjuvant tamoxifen therapy pp. 81-81(1) Authors: Dulley P.; Patel A.; Morgan M.; Bradpiece H.; Fawcett I.
Estrogen receptor and expression in human breast cancer tissues analysed by RT-PCR pp. 81-82(2) Authors: Kobayashi S.; Iwase H.; Omoto Y.; Hara Y.; Ando Y.
Urokinase-like plasminogenactivator (uPA) and plasminogenactivator-inhibitor type 1 (PAI-1) in primary breast cancer - Predictive markers for tamoxifen resistance? pp. 82-82(1) Authors: Kahlert S.; Boettcher B.; Konecny G.; Bauerfeind I.; Nestle-Kraemling C.; Untch M.
Hormone replacement therapy does not influence pathological stage of breast cancer in 1113 tumours pp. 82-82(1) Authors: Stallard S.; Litherland J.; Cordiner C.; Mallon E.; Dobson H.; George W.D.; Hole D.J.
Women taking hormone replacement therapy develop low grade tumours pp. 82-82(1) Authors: Iddon J.; Harding C.; Boggis C.; Bundred N.J.
Change in expression of ER and BCL-2 predict for quality and duration of response in endocrine sensitive breast cancer pp. 82-82(1) Authors: Kenny F.S.; Willsher P.C.; Gee J.M.W.; Nicholson R.I.; Ellis I.O.; Robertson J.F.R.
Arimidex, tamoxifen alone or in combination (ATAC) adjuvant trial in post-menopausal breast cancer pp. 83-83(1) Authors: Houghton J.; Baum M.
Endometrial changes caused by tamoxifen pp. 83-83(1) Authors: Rayter Z.; Watt M.; Keay S.; Jenkins J.; Wardle P.
Adrenomedullin: A potential autocrine growth factor for human breast epithelial cells during development and carcinogenesis pp. 83-83(1) Authors: Miller J.M.; Martinez A.; Moody T.; Jahnke G.; Smith L.; Brown P.; O'Connell P.; Cuttitta A.F.C.
A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in female nude mice pp. 83-83(1) Authors: Kurebayashi J.; Yamamoto S.; Otsuki T.; Sonoo H.
Androstenedione (A) conversion in lymphocytes infiltrating breast cancer (BC) tissue pp. 83-84(2) Authors: Berstein L.M.; Poroshina T.E.; Zimarina T.S.; Larionov A.A.; Uporov A.V.
11-hydroxysteroid dehydrogenase activity in human breast cancer cells: Characterization and effect of hormonal manipulations pp. 84-84(1) Authors: Arcuri F.; Sestini S.; Carducci A.; Manzoni F.; Schurfeldt K.; Parigi S.; Cintorino M.
Inherited susceptibility to breast cancer: A psychological perspective pp. 84-84(1) Author: Cull A.
Inherited predisposition to breast cancer pp. 84-84(1) Author: Daly P.A.
Genetic testing and its impact on a cohort of women and their families pp. 84-84(1) Author: Ormiston W.J.
Contra: Genetic testing should not be discouraged pp. 87-87(1) Author: Klijn J.G.M.
Pro: Genetic testing should be discouraged pp. 87-87(1) Author: Baum M.
Facts and figures from the meta-analyses in breast cancer pp. 88-88(1) Authors: Peto R.; Clarke M.; Collins R.; Davies C.; Godwin J.; Gray R.
Adjuvant systemic treatment for operable breast cancer - Standard therapies and new approaches pp. 88-88(1) Author: Goldhirsch A.
BIG - The breast intergroup pp. 88-88(1) Author: Piccart M.J.
The place of modern radiotherapy in loco-regional control and long-term survival in breast cancer pp. 88-88(1) Author: Cutuli B.
Breast cancer in Europe - Why outcomes are different? pp. 89-89(1) Author: Burns H.
Optimal follow-up after primary treatment pp. 89-89(1) Author: Ciatto S.
Developments in the palliation of metastatic bone disease pp. 90-90(1) Author: Coleman R.E.
A new standard treatment for advanced premenopausal breast cancer: A meta-analysis of the Combined Hormonal Agent Trialists Group (CHAT) pp. 90-90(1) Authors: Klijn J.G.M.; Blamey R.W.; Boccardo F.; Tominaga T.; Jonat W.; Kaufmann M.; Beex L.; Mauriac L.; Hoctin-Boes G.; Duchateau L.; Sylvester R.
Phase III trial comparing epirubicin/paclitaxel vs epirubicin/cyclophosphamid as first line treatment in metastatic breast cancer: Preliminary results of a German AGO trial pp. 90-90(1) Authors: von Minckwitz G.; Kuhn W.; Thomssen C.; Untch M.; Bauknecht T.; Eidtmann D.; Mobus V.; du Bois A.; Luck H.-J.
Epirubicin (E) plus paclitaxel (P) vs epirubicin followed by paclitaxel in metastatic breast cancer (MBC): An ongoing pharmacoeconomic study pp. 90-90(1) Authors: Redaelli A.; Baldini E.; Salvadori B.; Conte P.F.; Carnino F.; Guarneri M.; Svanosio M.; Dongiovanni V.
Activity of exemestane, an irreversible, oral, aromatase inhibitor in metastatic postmenopausal breast cancer patients (MBC) failing tamoxifen (TAM) pp. 91-91(1) Authors: Kvinnsland S.; Anker G.; Dirix L.Y.; Bonneterre J.; Prove A.M.; Wiking N.; De Belder K.; Mariani O.; Di Salle E.; Massimini G.
CMF and mitoxantrone in elderly patients with advanced breast cancer. A randomized phase II study pp. 91-91(1) Authors: Nooij M.A.; Steenland E.; Beex L.V.A.M.; van de Bos B.; Ruiter L.; Haes J.C.J.M.
Surgical treatment of vertebral breast cancer metastatsis pp. 91-91(1) Authors: Gligorov J.; Garreau de Loubresse C.; Debourdeau P.; Pirriou P.; Andrei T.; Lotz J.P.; Judet T.
Breast cancer screening pp. 91-91(1) Author: Amadori D.
Use of hormone replacement therapy and the sensitivity of screening mammography pp. 92-92(1) Authors: Kavanagh A.; Mitchell H.; Giles G.
Mammography screening in Norway. Is it cost effective? pp. 92-92(1) Author: Norum J.
Russia (St.-Petersburg)/WHO randomized prospective study of the role of BSE in reduction of breast cancer mortality pp. 92-92(1) Authors: Semiglazov V.; Moiseyenko V.; Protsenko C.; Kharikova R.; Manihas A.
Ostergotland mammographic screening programme: Compliance, referral rate, and risk of interval breast cancer after a negative screen pp. 92-92(1) Authors: Vitak B.; Carstensen J.; Stat O.
Screening women with a family history of breast cancer - Results from a national audit pp. 92-93(2) Author: Macmillan R.D.
Is annual mammography better to detect a contralateral breast cancer than mammography at a greater interval? pp. 93-93(1) Authors: Kaas R.; Hart A.A.M.; Rutgers E.J.T.; Peterse J.L.; Besnard A.P.E.
Continuing education and results in breast cancer screening pp. 93-93(1) Authors: Rijken H.; Hendriks J.; Holland R.
Screening - Yes, but whom and when? pp. 93-93(1) Author: von Kleist S.
Can population based screening reduce the mortality from breast cancer? pp. 93-93(1) Authors: Kingsmore D.B.; Hole D.; Gillis C.R.; George W.D.
Symptomatic status, mammographic sensitivity and screening policy pp. 93-94(2) Authors: Kavanagh A.; Mitchell H.; Giles G.
Pre-operative diagnosis of screen detected cancers: Increasing the diagnostic rate pp. 94-94(1) Authors: Bradpiece H.A.; Khot U.P.; Patel A.R.; Morgan M.W.E.
A model of elderly Latina's breast screening decisions pp. 94-94(1) Authors: Veit C.; Clairice T.
Effectiveness of mammographic screening for breast cancer in women aged over 50 years in Japan pp. 94-94(1) Authors: Morimoto T.; Sasa M.; Yamaguchi T.; Kondo H.; Sagara Y.
Factors influencing women's decisions to undergo genetic testing for breast cancer pp. 94-94(1) Authors: Cappelli M.; Surh L.D.; Logan S.V.; Hunter A.; Humphreys L.; Allanson J.
Improvements in survival from the NHS mammographic screening programme - A single centre study pp. 94-95(2) Authors: Chan H.; Harris L.A.; Shepstone B.; English R.; Greenall M.J.
Results of mammographic screening 1994-1997 pp. 95-95(1) Authors: Baldi V.; Cicalese A.; Coppola G.; Scarano M.; Gatto E.
The experience of breast cancer screening pp. 95-95(1) Authors: Levshin V.; Fedichkina T.; Droggachih V.
Mass-screening for breast cancer in Japan pp. 95-95(1) Authors: Fujishima N.; Itoh S.; Yamakawa T.; Izumi K.; Sugimoto T.; Yoshida M.
Results of screening in a positive family history clinic pp. 95-95(1) Authors: Lamont M.; Sheridan A.; Rayter Z.
Can the mortality of breast cancer be reduced? pp. 95-96(2) Authors: Kingsmore D.B.; Hole D.; Gillis C.R.; George W.D.
Experimental pathology and breast cancer genetics: Looking at malignant and premalignant tissues using new technologies pp. 96-96(1) Authors: Osin P.; Shipley J.; Lui Y.J.; Crook T.; Gusterson B.A.
Survival patterns according to age and treatment among breast cancer patients pp. 96-96(1) Authors: Kroman N.; Jensen M.; Wohlfahrt J.; Mouridsen H.T.; Andersen P.K.; Melbye M.
Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: A case-control study of histological factors and alterations in oncogene expression pp. 96-96(1) Authors: Elkhuizen P.H.M.; Voogd A.C.; van den Broek L.C.J.M.; Tan T.C.; van Houwelingen H.C.; Leer J.W.H.; van de Vijver M.J.
A classification of breast cancer based on contrast enhanced MRI pp. 96-96(1) Authors: Douek M.; Davidson T.; Hall-Craggs M.A.; Lakhani S.R.; Taylor I.
Predictive value of vascular endothelial growth factor (VEGF) for overall survival in estrogen receptor positive breast carcinoma pp. 97-97(1) Authors: Linderholm B.; Tavelin B.; Grankvist K.; Henriksson R.
Importance of tissue-infiltrating macrophage activation in breast cancer progression pp. 97-97(1) Authors: Toi M.; Ueno T.; Matsumoto H.; Yamamoto Y.; Ishigaki S.; Tominaga T.
The higher local recurrence rate after breast conserving therapy in young patients explained by larger tumour size, incomplete excision at first attempt and smaller excision volume? pp. 97-97(1)
Evaluation of biological prognostic factors in relation to local recurrence after breast conserving therapy pp. 97-97(1) Authors: Meijer-van Gelder M.E.; Look M.P.; Klijn J.G.M.; Foekens J.A.
Familiar history in breast conservative treatment of breast cancer a good prognostic factor? pp. 98-98(1) Authors: Jobsen J.J.; Meerwaldt J.H.; Helle P.A.; Mulder H.J.; Noach P.
Differential impact of high steroid hormone receptor concentrations on overall survival (OS) in primary breast cancer subgroups pp. 98-98(1) Authors: Struse K.; Audretsch W.; Rezai M.; Pott G.; Bojar H.
Analysis of variables associated with recurrence/metastasis in breast cancer tumor of =<1 cm pp. 98-98(1) Authors: Tubiana-Hulin M.; Hacene K.; Cvitkovic-Berthreault F.
Does prior pregnancy influence breast cancer outcome in young women? pp. 98-98(1)
Expression of the apoptosis-related genes c-myc, p53 and bcl2 in breast carcinomas from operable patients. Only bcl2 expression is associated with a lower risk of death pp. 98-99(2) Authors: Riou G.; Mathieu M.C.; Spielmann M.; Le M.G.
Prognostic significance of p53 mutations in the zinc-binding domains (L2/L3) in lymph node-positive breast cancer patients pp. 99-99(1) Authors: Kucera E.; Mayerhofer K.; Seifert M.; Kainz C.; Sliutz G.; Zeillinger R.
mRNA determination of estrigen receptor, progestin receptor, pS2. PAI-1 by competitive reverse transcription-PCR in human breast cancer pp. 99-99(1) Authors: Tong D.; Schneeberger C.; Czerwenka K.; Schmutzler R.K.; Kucera E.; Kainz C.; Seifert M.; Zeillinger R.; Sliutz G.
Medullary breast carcinoma. Ten-year results in 108 patients treated in a single center pp. 99-99(1) Authors: Dendale R.; Campana F.; Vincent-Salomon A.; de Cremoux P.; de la Rochefordiere A.; Fourquet A.
Anti-apoptotic phenotype is associated with decreased loco-regional recurrence rate in breast cancer pp. 99-100(2) Authors: Jager J.J.; Jansen R.L.H.; Arends J.W.; Joosten-Achjanie S.; Volovics L.; Schouten L.J.; de Jong J.M.A.; von Meyenfeldt M.F.; Blijham G.H.
Can assessment of angiogenesis, proliferation and apoptosis predict the need for adjuvant therapy in breast cancer? pp. 100-100(1) Authors: van Dam P.; Tjalma W.; Bogers J.; Weyler J.; Dewulf M.; Voet G.; Hellemans P.; Van Marck E.; Buytaert P.
CA-15.3: Prognostic factor in breast cancer pp. 100-100(1) Authors: Vialard F.; Basuyau J.P.; Gligorov J.; Boccara C.; Graic Y.; Veyret C.; Julien J.P.
Prognostic significance of keratins in breast cancer pp. 100-100(1) Author: Grabau A.D.
Neural networks improve the prediction of survival in breast cancer pp. 100-100(1) Authors: Drew P.J.; Magee P.; Bottaci L.; Menon M.; Heer K.; Carleton P.J.; Fox J.N.; Monson J.R.T.; Kerin M.J.
Local recurrence (LR) after breast-conserving therapy (BCT) in node-negative premenopausal patients: Influence of perioperative chemotherapy (PeCT) pp. 101-101(1) Authors: Elkhuizen P.H.M.; van Slooten H.J.; van de Velde C.J.H.; Clahsen P.C.; van den Broek L.C.J.M.; van de Vijver M.J.
The occurrence of deletions and point mutations in the estrogen receptor gene in breast cancer specimens pp. 101-101(1) Authors: Winstanley J.H.R.; Irwin S.; Barraclough R.; Sibson R.
Tenascin-C expression in invasion border of early breast cancer - A predictor of local and distant recurrence pp. 101-101(1) Authors: Jahkola T.; Toivonen T.; Virtanen I.; von Smitten K.; Nordling S.; von Boguslawski K.; Haglund C.; Nevanlinna H.; Blomqvist C.
Age the limiting factor for breast conservative treatment in T1 breast cancer? pp. 101-101(1) Authors: Jobsen J.J.; Meerwaldt J.H.; Mulder H.J.; v. Reijn M.
Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in macrophages correlates with tumor angiogenesis and prognosis in breast cancer pp. 101-102(2) Authors: Nagaoka H.; Iino Y.; Takei H.; Horiguchi J.; Maemura M.; Koibuchi Y.; Matumoto H.; Yokoe T.; Morishita Y.
Tumour angiogenesis by vascular grading is of prognostic significance in breast cancer pp. 102-102(1) Authors: Hansen S.; Grabau D.A.; Bak M.; Sorensen F.B.
Multivariate analysis of prognostic factors in lymph node negative breast cancer pp. 102-102(1) Authors: Ross J.S.; Muraca P.J.; Jaffe D.; Morgan T.; Fletcher J.A.
Independent role of p53 expression and reduction in kinetic cell activity in predicting clinical complete response (CR) to primary chemotherapy in breast cancer (BC) patients pp. 102-102(1) Authors: Bottini A.; Berruti A.; Bersiga A.; Brizzi M.P.; Brunelli A.; Cirillo F.; Aguggini S.; Bertoli G.; Alquati P.; Dogliotti L.
Menstrual phase and timing of breast cancer surgery: Statistical aspects pp. 102-103(2) Authors: Haeusler G.; Tempfer C.; Heinzel H.; Kainz C.
A comparison of biochemical quantitative and immunohistochemical detection methods for the detection of the erbB2 oncoprotein in breast cancer tissue pp. 103-103(1) Authors: Giersig C.; Opri F.; Torsten U.
Expression of cytosolic thymidine kinase in the proliferative breast carcinoma after primary chemotherapy: Therapeutic indication pp. 103-103(1) Authors: Gachon F.; Charrier S.; Kwiatkowski F.; Besse G.; Cure H.; Chassagne J.; Ferriere J.P.; Penault-Llorca F.; Dauplat J.; Chollet P.
In vivo bromodeoxyuridine (BrdUrd) labeling index as a prognostic marker in human breast cancer pp. 103-103(1) Authors: Goodson W.H.; Moore D.H.; Ljung B.-M.; Chew K.; Mayall B.; Smith H.S.; Waldman F.W.
Tc-99 Tetrofosmin scintimammography in determining prognostic characteristics of breast cancer pp. 103-103(1) Authors: Flanagan F.; Bergin D.; Phelan N.; Ennis J.T.
HER-2/neu oncogene amplification in breast cancer pp. 103-104(2) Authors: Brien T.P.; Sheehan C.E.; Muraca P.J.; Stylos S.; Johnson R.L.; Ross J.S.
Prognostic factors in human breast cancer pp. 104-104(1) Authors: Storace A.; Borgiani L.; Tunesi G.; Casazza S.; Pastorino A.; Bandelloni R.
Axillary node involvement in T1 breast cancer in pre-menopausal Chinese pp. 104-104(1) Authors: Hsu M.H.; Hsieh C.B.; Yu J.C.; Liu Y.C.; Chang T.M.
The local recurrence after breast conserving surgery: The prognosis and the diagnosis pp. 104-104(1) Authors: Izquierdo M.; Fabregas R.; Prats M.; Fernandez-Cid A.; Suris J.C.; Marin L.L.; Feu J.; Grases P.
Significance of soluble interleukin-2 receptors and natural killer cells in breast cancer pp. 104-104(1) Authors: Cabrini L.; Marelli M.; Spampatti G.; Frattini V.; Maroni P.; Gambarini S.; Calvi A.; Colombo L.
Thymidylate synthetase levels in breast cancer: A predictor for early prognosis and outcome of adjuvant chemotherapy pp. 104-105(2) Authors: Yamamoto N.; Miyauchi M.; Sisikura T.
A proposed prognostic factor for node-negative invasive breast carcinomas: Evaluation based on the intraductal component, particularly the presence of comedo-type necrosis pp. 105-105(1) Authors: Yagata H.; Harigaya K.; Suzuki M.; Oshida M.; Nagashima T.; Hashimoto H.; Shishikura T.; Ishii G.; Nakajima N.; Mikata A.
Relationship between tumor shrinkage and changes kinetic cell activity after primary chemotherapy (PC) in breast cancer (BC) patients pp. 105-105(1) Authors: Bottini A.; Berruti A.; Bersiga A.; Brizzi M.P.; Brunelli A.; Betri E.; Filippini L.; Bertoli G.; Alquati L.; Dogliotti P.
Relationship between estrogen receptor (ER) status in primary breast cancer (BC) specimens and serum CA 15-3 levels at first relapse of disease pp. 105-105(1)
Prognosis of 56 male breast cancers - Comparison with females pp. 105-106(2) Authors: Herman K.; Stelmach A.; Mitus J.; Skotnicki P.; Kusy T.
Prognosticators in axillary node negative breast cancer pp. 106-106(1) Authors: Fiets W.E.; Blankenstein M.A.; Nortier J.W.R.; Rultenberg H.M.; Rutgers D.H.; Hennipman A.; Gimbrere C.H.F.; Strulkmans H.
Functional intravital assay of anticancer drug efflux transporters in breast cancer biopsy specimens pp. 106-106(1) Authors: Bogush T.; Smirnova G.; Koldaeva E.; Bogush E.; Kirsanov V.; Komov D.; Khailenko V.
Depression as prognostic factor in breast cancer pp. 106-106(1) Authors: Jorgensen T.; Olsen E.; Keiding N.; Mouridsen H.; Mortensen P.B.; Hjerl K.
Loco-regional recurrence in randomized trial of breast cancer TNM stage II. Prognostic factors pp. 106-106(1) Authors: Tennvall-Nittby L.; Tengrup I.; Anagnostaki L.
The significance of prostate specific antigen (PSA) in breast cancer pp. 106-107(2) Authors: Klijn J.G.M.; Diamandis E.P.; Yu H.; Look M.P.; Meijer-van Gelder M.E.; van Putten W.L.J.; Foekens J.A.
The relationship between nm23 gene expression and distal metastasis and prognosis in breast cancer pp. 107-107(1) Authors: Huisheng M.; Hong L.; Shuling L.; Xilin F.; Yumei F.
New era of treatment in breast cancer - Neoadjuvant therapy without surgery pp. 107-107(1) Authors: Bretz P.D.; Dreisbach P.B.; Kaminsky D.B.; Bacus S.S.
Lymphocyte subgroups in breast cancer and the effect of tumor removal pp. 107-107(1) Authors: Balaban F.; Baskan S.; Kocak S.; Aydintug S.
Assessment of the response with color-doppler sonography (CDS) in patients affected by breast cancer (BC) in neoadjuvant chemotherapy (NCT) pp. 107-107(1) Authors: Filippelli G.; Birmonte R.; Conforti S.; Crispino G.; Liguori V.; Pomillo A.; Rovito A.; Palazzo S.
Prognostic markers in neoadjuvent chemotherapy pp. 107-108(2) Authors: Green L.; Rayter Z.; Calder C.; Fardon J.R.
Male breast cancer: A 20 year review of 60 patients in Slovenia pp. 108-108(1) Authors: Juznic T.; Cofer T.; Borstnar S.
Change of Cu/Zn-superoxide dismutase in breast cancer tissue related to the tumor proliferation and differentiation being one of prognostic indicators pp. 108-108(1) Authors: Yamamoto H.; Iwase K.; Kato K.; Ohtani S.; Tsujimura T.; Hanai T.; Inagaki A.; Jimbo S.; Kobayashi N.; Asano Y.; Furusawa K.; Miura K.
Significance of blood flow analysis using color doppler ultrasound for prediction of relapse in patients with breast cancer pp. 108-108(1) Authors: Konishi Y.; Hashimoto T.; Tachibana T.; Kajiwara T.
Surgeon's related quality of breast cancer surgery pp. 108-108(1) Authors: Herman K.; Kusy T.; Stelmach A.; Kalita A.
Prognostic importance of active thermography in breast cancer pp. 108-109(2) Authors: Mazurin V.; Tsurkan A.; Pikhut P.; Moskalyova L.
Histopathologic basis for axillary sampling pp. 109-109(1) Author: Cserni G.
DNA flow cytometry in breast carcinoma (BC): Comparison with clinical outcome pp. 109-109(1) Authors: Bogatyrev V.N.; Portnoj S.M.; Koptiaeva I.V.; Laktionov K.P.; Balakireva G.V.
Breast cancer under age 35 - In what way should we treat the patients pp. 109-109(1) Authors: Jeziorski A.Z.; Piekarski J.; Berner J.
Prognostic factors in patients with recurrent breast cancer following mastectomy pp. 109-109(1) Authors: Icli F.; Cay F.; Dincol D.; Karaoguz H.; Demirkazik A.; Akbulut H.
The use of p65 in generating the prognosis in female breast cancer pp. 109-110(2) Authors: Niewiadomska H.; Stempien M.; Mirowski M.; Jeziorski A.
Prognosis of the typical medullary carcinoma of the breast pp. 110-110(1) Authors: Stelmach A.; Herman K.; Mitus J.
R2: Index of biological aggressive breast cancer pp. 110-110(1) Authors: Cherubini M.; Baxa P.; Sustersich M.; Mustacchi G.
Receptor findings and menstrual status at radical operations due to breast carcinoma pp. 110-110(1) Authors: Kocic M.; Inic M.; Juskic M.; Pralica J.; Nikolic V.; Marjanovic B.
Intratumoral beta-radiometry is an universal test of breast cancer (BC) activity pp. 110-110(1) Authors: Portnoi S.M.; Lactionov K.P.; Gaboonia R.I.; Godin V.P.; Shiriaev S.V.
Mammary mucin secretion: A modern revisitation and review pp. 110-111(2) Author: Davies J.D.
Loss of heterozygosity (LOH) in normal epithelial and myoepithelial cells from tissues adjacent to breast carcinoma pp. 111-111(1) Authors: Lakhani R.S.; Chaggar R.; Davies S.; Odell C.; O'Hare M.
Loss of heterozygosity (LOH) and allelic imbalance (Al) in apocrine metaplasia and apocrine adenosis of the breast pp. 111-111(1) Authors: Selim S.; Ryan A.; Wells C.
An audit of grading and typing of invasive breast carcinoma on needlecore biopsy specimens pp. 111-111(1) Authors: Denley H.E.; Pinder S.E.; Elston C.W.; Ellis I.O.
The prediction of response to chemotherapy in invasive breast carcinoma by determination of histological grade pp. 111-111(1) Authors: Pinder S.E.; Murray S.; Ellis I.O.; Trihia H.; Elston C.W.; Gelber R.D.; Goldhirsch A.; Lindtner J.; Cortes-Funes H.; Simoncini E.; Byrne M.J.; Golouh R.; Rudenstam C.M.; Castiglione-Gertsch M.
Predictive factors of response to neo-adjuvant chemotherapy by immunohistochemistry (IHC) pp. 111-112(2) Authors: Grogan G.M.; Mauriac L.; Durand M.; Bonichon F.; Floquet A.
The expression of thymidine phosphorylase in fibrocystic disease, fibroadenoma, papilloma and carcinoma of breast pp. 112-112(1) Authors: Yonenaga F.; Takasaki T.; Ohi Y.; Yagara A.; Yoshida H.
Power doppler vascularity in malignant breast tumours: Correlation with pathological blood vessel counts, microvessel density and other histopathological prognostic factors pp. 112-112(1) Authors: Teh W.L.; Denley H.E.; Pinder S.E.; Ellis I.O.; Evans A.J.; Wilson A.
A national pathology audit of breast cancer cases pp. 112-112(1) Authors: Kricker A.; Smith C.; Bilous M.; Armstrong B.
Comparative studies on cytological findings between early recurrent cases with negative nodes and recurrence-free cases with positive nodes in breast cancer pp. 112-112(1) Authors: Kawano K.; Miyayama H.; Nishimura R.; Nagao K.
Histiocytoid breast carcinoma: Histopathological study and a proposal of the diagnostic criteria pp. 113-113(1) Authors: Shimizu S.; Kitamura H.; Itoh T.; Nakamura T.; Matsukawa H.; Fujisawa J.
Analysis of 47 breast lesions screen detected treated by surgical biopsy: Surgical margin status and presence of residual tumor at the surgical reexcision pp. 113-113(1) Authors: Cuccorese C.; Mano M.P.; Ponti A.; Bordon R.; Arisio R.; Mingrone K.
Expression of S100- and S100- in atypical papilloma, atypical papillomatosis and atypical intraductal hyperplasia of the breast pp. 113-113(1) Authors: Ichihara S.; Koshikawa T.; Endo T.; Sato Y.; Ohno M.; Aoyama H.; Kato K.
Biologic markers in small cancers of the breast and breast preneoplastic lesions pp. 113-113(1) Authors: Krogerus L.; Leivonen M.; Hasto A.-L.
Predicting the prognosis of breast carcinoma - What the pathologist should do? pp. 114-114(1) Authors: Kulka J.; Loth S.; Tokes A.-M.; Kuhn C.; Kadar A.
Cellbiological factors in relation to nuclear grade and growth pattern pp. 114-114(1) Authors: Ferno M.; Idvall I.; Andersson C.; Fallenius G.; Ingvar C.; Ringberg A.; Strand C.; &unknown;9kerman M.
Image analysis of imprint cytology from invasive breast carcinoma and its relation to axillary node metastasis pp. 114-114(1) Authors: Idvall I.; Ingvaldsson L.; Knutsson Y.; Linden T.; Ferno M.
Nuclear abnormalities (nuclear pockets) in apocrine breast carcinoma: Report of a case pp. 114-114(1) Authors: Stravoravdi P.; Grekou A.N.; Patakiouta P.; Tsoukalas T.; Toliou T.; Dimitriadis K.
Adenoid cystic carcinoma of the breast: About 14 new cases pp. 114-114(1) Authors: Vlastos G.; Validire P.; Clough K.B.
Aggressive fibromatosis of the breast. Clinical, pathological & mammographic findings pp. 115-115(1) Author: Govoni A.F.
The expression of proliferating antigen Ki67 and PCNA and products of suppressor gene p53 in primary invasive ductal carcinoma of female breast pp. 115-115(1) Authors: Niewiadomska H.; Jeziorski A.; Mirowski M.; Blonski J.
Estrogen receptor analysis on breast cancer imprints pp. 115-115(1) Authors: Fallenius G.; Ferno M.; Isola J.
Case report: Primary neuroendocrine tumour of the breast pp. 115-115(1) Authors: Vernet M.; Checa M.A.; Ferrer D.; Lloreta J.; Carreras R.
Stromelysin-3 (ST3), from basic research to molecular medicine pp. 115-115(1) Authors: Rio M.C.; Masson R.; Lefebvre O.; Chenard M.P.; Noel A.; Bellocq J.P.; Basset P.
Molecular mechanisms leading to C-ERBB2 gene overexpression in breast cancers pp. 115-116(2) Authors: Winkler M.; Grooteclaes R.; Vernimmen D.; Plaza S.; Pasleau
Neu differentiation factor (NDF/heregulin) induces expression of adhesion molecules, increased cellular invasiveness, and is expressed in Paget's disease of the breast together with its receptors pp. 116-116(1) Authors: Bacus S.; Yarden Y.; Kaminsky D.
Multisite phosphotyping of the ErbB2 oncoprotein in 102 human breast cancers pp. 116-116(1) Authors: Ouyang X.; Gulliford T.; Shousha S.; Epstein R.J.
Mutations in the p53 gene, both within and outside the zinc-binding domains, are associated with increased apoptosis and mitosis in invasive breast carcinomas pp. 116-116(1) Authors: van Slooten H.-J.; van Vijver M.J.; Borresen A.-L.; Eyfjord J.E.; Valgarodottir R.; Scherneck S.; Nesland J.M.; Devilee P.; Cornelisse C.J.; van Dierendonck J.H.
ICAM-1 up-regulation expression on breast cancer cell lines after all-trans retinoic acid (ATRA) treatment is independent of hormonal receptor conditions pp. 116-117(2) Authors: Bai G.; Arnulfo A.; Deaglio S.; Calosso L.; Capelli P.; Salini A.; Malavasi F.; Surico
Serum soluble VCAM: A surrogate marker of angiogenesis pp. 117-117(1) Authors: Byrne G.J.; Blann A.D.; Venizelos V.; Howell N.J.; Bundred A.
Ovarian hormones effect VEGF expression in breast cancer cells pp. 117-117(1) Authors: Heer K.; Kumar H.; Speirs V.; Drew J.P.; Monson R.T.J.; Kerin J.M.
Breast cancer tissue analysis by computerized bidimensional polyacrylamide gel electrophoresis (2DPAGE) and N-terminal microsequencing pp. 117-117(1) Authors: Bini L.; Magi B.; Mazzocchi B.; Arcuri F.; Tripodi S.; Cintorino M.; Sanchez J.-C.; Frutiger S.; Hughes G.; Pallini V.; Hostrasser D.F.
Cytogenetic analysis of 112 breast tumors pp. 117-117(1) Authors: Penault-Llorca F.; Perissel B.; deLatour M.; Fouilhoux Y.; Faugeras Y.; Chassagne J.; Besse G.; Malet P.; Fonck Y.
Primary paclitaxel in breast cancer: Is beta-tubulin a predictor for pathological response? pp. 117-118(2) Authors: Formenti C.; Danenberg S.; Danenberg P.
Proliferation, apoptosis and related markers in invasive ductal breast carcinoma pp. 118-118(1) Authors: Buytaert P.; Tjalma W.; Bogers J.; Dewulf M.; Weyler J.; Voet G.; Hellemans P.; van Dam P.; Van Marck E.
Incidence of breast cancer associated with use of hormone replacement therapy and other risk factors in 1709 patients pp. 118-118(1) Authors: Gehani S.; Khan Z.; Parbhoo S.
Breast cancer and missense mutations in the transactivation region of the BRCA1 gene pp. 118-118(1) Authors: Garcia J.M.; Dominguez G.; Silva J.M.; Gonzalez R.; Navarro M.A.; Corbacho C.; Martinez G.; Villanueva M.J.; Navarro F.; Bonilla F.
The expression of new protein taking part in cancerogenesis, p65, and its correlation with steroid receptors in ductal carcinoma of female breast pp. 118-118(1) Authors: Niewiadomska H.; Jeziorski A.
A prospective study on genetic risk factors in an unselected sample of breast cancer patients who receive adjuvant radiotherapy pp. 118-119(2) Authors: Warlam-Rodenhuis C.C.; Gimbrere C.H.F.; van Helvoirt R.P.; van der Wiele K.E.; Vasen H.F.A.; van der Luyt R.B.; Ausems M.G.E.M.
CIP-1 Protein expression in node-positive breast cancer patients pp. 119-119(1) Authors: Hupperets P.; Thunnissen E.; Peterse J.; Schouten H.
A study of correlation between DNA ploidy pattern and aberration of chromosome 8 detected by fluorescence in situ hybridization in human breast cancer pp. 119-119(1) Authors: Hara S.; Terada R.S.; Ayabe H.; Tagawa Y.
The antioxidant status of breast cancer patients pp. 119-119(1) Author: Korman D.
Presurgery chemotherapy and DNA ploidy of the adenocarcinoma breast cells pp. 119-119(1) Authors: Nikolaeva T.; Dobrynin Y.
p-Glycoprotein (pGP) and p53 expression in primary breast cancer pp. 119-120(2) Authors: Betta P.G.; Bottero G.; Cosimi M.F.; Spinoglio G.; Pavesi M.; Pastomerlo M.
Induction of PCD with doxorubicin in invasive lobular carcinoma cells of human breast by circumventing MDR-1 with colloidal phosphorothioate pp. 120-120(1) Authors: Giannios J.; Ginopoulos P.
Psychosocial oncology: Where are we now? pp. 120-120(1) Author: Cull A.
Does psychological response influence survival from breast cancer? pp. 120-120(1) Authors: Watson M.; Haviland J.S.; Greer S.; Davidson J.; Bliss J.M.
Depression subsequent to breast cancer pp. 120-120(1) Authors: Hjerl K.; Olsen E.; Keiding N.; Mortensen P.B.; Jorgensen T.
Psychosocial implications of prophylactic bilateral mastectomy pp. 120-120(1) Authors: Hatcher M.B.; Fallowfield L.J.; Thirlaway K.; Hall A.
Psychosocial impact of endocrine therapy for breast cancer on women's quality of life pp. 121-121(1) Authors: Leaity S.; Fallowfield L.; Benson S.; Howell A.
Psychosocial compliance and response rates in a chemoprevention randomised control trial of women at high risk to breast cancer pp. 121-121(1) Authors: West A.; Fallowfield L.J.
Attitudes of medical students towards a woman with metastatic breast cancer pp. 121-121(1) Authors: Cheung K.L.; Patil N.G.
Stress of daily activities and risk of breast cancer: A prospective cohort study in female twins in Finland pp. 121-121(1) Authors: Lillberg K.; Verkasalo P.K.; Kaprio J.; Teppo L.; Koskenvuo M.
Patient evaluation of hormone therapy in breast cancer: Quantifying trade-offs between survival gains and quality of life pp. 122-122(1) Authors: Fellowes D.; Fallowfield L.; Saunders C.; Houghton J.
On the way towards integration: A psycho-educational group for breast cancer patients pp. 122-122(1) Authors: Leysen B.; Goethals B.; Buytaert P.; Van Dam P.
Quality of life - An essential aspect in the follow-up care of patients with breast cancer pp. 122-122(1) Authors: Bastian U.; Koller M.; Kopp I.; Hild F.; Fenner N.; Vogel A.; Schmitz S.; Thommes S.; Lorenz W.; Schulz K.-D.
Assessing the psychological functioning and health care choices of adolescent daughters of breast cancer patients pp. 122-122(1) Authors: Cappelli M.; Verma S.; Korneluk Y.; Tomiak E.; Degrasse C.; Corsini L.; Humphreys L.
Implications of social support for survivors of breast cancer pp. 122-122(1) Author: Gorin S.S.
Breast cancer in elderly patients: Psychosocial aspects of rehabilitation pp. 123-123(1) Authors: Strada M.; Gabanelli P.; Lodola E.; Cuzzoni Q.; Bernardo A.; Plastina M.; Bernardo G.
Presymptomatic testing for hereditary breast/ovarian cancer (HBOC): Is there psychological distress in the pre-test period? pp. 123-123(1) Authors: Lodder L.N.; Frets P.G.; Trijsburg R.W.; Dudok de Wit A.C.; Tibben A.; Meijers-Heijboer E.J.; Klijn J.G.M.; Seynaeve C.; Niermeijer M.F.
Quality of life of breast cancer patients in different clinical phases pp. 123-123(1) Authors: Chie W.C.; Huang C.S.; Chen J.H.; Chang K.J.
A comparison of body image in post-mastectomy and breast reconstruction patients pp. 123-123(1) Authors: Hopwood P.; Tillott R.; Baildam A.
Psychological impact of genetic counselling and testing on women at high risk of developing breast cancer: Preliminary findings pp. 123-123(1) Authors: Meiser B.; Tucker K.; Butow P.N.; Barratt A.L.; Clifton M.
The patient's perception of her breast following irradiation (XRT) for early breast cancer (EBC) pp. 124-124(1) Authors: Amichetti M.; Caffo O.; Mussari S.; Chiappe E.; Brugnara S.; Galligioni E.; Tomio L.
Predictors of emotional well-being and quality of life in women with primary breast cancer pp. 124-124(1) Authors: Vos P.J.; Garssen B.
Establishing a comprehensive hospital-based breast cancer support organisation pp. 124-124(1) Authors: Freilich G.; Parbhoo S.P.
An assessment of anxiety levels of women attending for the first outpatient appointment for breast care pp. 124-124(1) Authors: Durning P.; Morris E.; Gash A.; Gray J.
Ceiling paintings above patients being examined reduce anxieties pp. 124-125(2) Author: Baratelli G.M.
Psychological and clinical quality of life determinants among women with breath cancer in different stages pp. 125-125(1) Authors: Zwaliqski M.; Majkowicz M.; Trzebiatowska I.A.; de Walden-Ga3uszko K.; Makarewicz H.
The influence of the early childhood family climate on later breast cancer morbidity pp. 125-125(1) Authors: Vegelj-Pirc M.; Snoj Z.
The meaning of life with women after breast cancer treatment pp. 125-125(1) Authors: Vegelj-Pirc M.; Zalokar-Divjak Z.; Musek J.; Puric F.
Stages of breast cancer: An Israeli psychosocial medical of intervention pp. 125-125(1) Authors: Sadeh-Tassa D.; Drory M.; Ginzburg K.; Stadler Y.
Proteolytic enzymes in prevention an treatment of lymphatic oedema of arm after axillary dissection or radiotherapy pp. 125-126(2) Authors: Machanova M.; Wald M.; Bechyne M.; Prausova J.; Adamek J.
Danazol versus cabergolina for the treatment of cyclic mastalgia pp. 126-126(1) Authors: Gioffre W.; Ditto A.; Tripodi A.; Ciatto S.
Subjective effects of pamidronate on pain, in patients with symptomatic bone metastases in advanced breast cancer pp. 126-126(1) Authors: Ferrero G.; Valle A.; Bertetto O.
Breast cancer in the elderly. The impact of histological features on the prognosis and survival pp. 126-126(1) Authors: Botos A.; Csaky G.; Minik K.
Long term survival in elderly breast cancer patients treated with tamoxifen (TAM) alone vs surgery followed by TAM pp. 126-126(1) Authors: Thomas R.; Capasso I.; de Matteis A.; Labonia V.; Landi G.; Nuzzo F.; Rossi E.; Montedoro D.; D'Aiuto M.; D'Aiuto G.T.; Melucci M.
Arm morbidity after primary breast cancer treatment in elderly women pp. 127-127(1) Authors: Tengrup I.; Tennvall L.
A 5-year audit of breast cancer treatment in the very elderly (85+ years) pp. 127-127(1) Authors: Vestey S.; Gallegos N.
Breast cancer in old Romanian women pp. 127-127(1) Authors: Onofriescu M.; Aldea M.-J.; Dragomir D.; Nemescu D.
Characteristics of breast cancer in elderly women pp. 127-127(1) Authors: Djordjevic M.; Rancic Z.; Djordjevic L.; Djordjevic R.; Djordjevic T.; Pesic M.; Jeremic M.; Gmijovic D.; Marjanovic H.B.; Stojiljkovic M.
Elderly breast cancer in Chinese women pp. 127-127(1) Author: Cheung K.L.
Introduction to cancer clinical trials pp. 128-128(1) Author: Therasse P.
Breast cancer clinical trials in Europe - What has been done and what is currently underway pp. 128-128(1) Author: Castiglione-Gertsch M.
The role of clinical trials and their impact on breast cancer management pp. 128-128(1) Author: Tannock I.F.
Issues around informed consent - Why and when should women participate in clinical trials? pp. 128-128(1) Author: Goodare H.
Shopping cart
RSS for latest issue
